Synthesis and Evaluation of Biological Activity of a ...
Transcript of Synthesis and Evaluation of Biological Activity of a ...
![Page 1: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/1.jpg)
Seton Hall UniversityeRepository @ Seton HallSeton Hall University Dissertations and Theses(ETDs) Seton Hall University Dissertations and Theses
Spring 5-14-2016
Synthesis and Evaluation of Biological Activity of aPotential Immunomodulatory ZwitterionicPolysaccharideVikram [email protected]
Follow this and additional works at: https://scholarship.shu.edu/dissertations
Part of the Biochemistry Commons, Immunology of Infectious Disease Commons, and theOrganic Chemistry Commons
Recommended CitationBasava, Vikram, "Synthesis and Evaluation of Biological Activity of a Potential Immunomodulatory Zwitterionic Polysaccharide"(2016). Seton Hall University Dissertations and Theses (ETDs). 2170.https://scholarship.shu.edu/dissertations/2170
![Page 2: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/2.jpg)
1
Synthesis and Evaluation of Biological Activity of a Potential
Immunomodulatory Zwitterionic Polysaccharide
A Dissertation
In the Department of Chemistry and Biochemistry submitted to the
faculty of the Graduate School of Arts and Sciences in partial
fulfillment of the requirements for the
degree of
Doctor of Philosophy
In Chemistry
at
Seton Hall University
by
Vikram Basava
May 2016
![Page 3: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/3.jpg)
2
© 2014 (Vikram Basava)
![Page 4: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/4.jpg)
3
![Page 5: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/5.jpg)
4
ACKNOWLEDGEMENTS
I am greatly thankful to the support and encouragement that I have received from Dr.
Cecilia H. Marzabadi. Her ideas and guidance have made this dissertation possible.
She always had the time to answer all my questions and let me try reactions with the
ideas which I came up with.
I would like to thank the Department of Chemistry and Biochemistry for giving me the
opportunity to pursue my PhD at Seton Hall University. I am extremely thankful for Dr.
Sergiu Gorun for helping me in getting the x-ray crystal structure of the anhydro sugar
which I synthesized. I would like to acknowledge Dr. Constantine Bitsaktsis for
performing biological tests on the PSA 1 analogue which was synthesized in my project.
I would again like to thank Dr. Bitsaktsis along with Dr. James E. Hanson for taking their
time to review my dissertation write-up.
I am thankful for the support of Dr. Robert L. Augustine and Dr. Setrak K. Tanielyan at
the CAC. I would even like to thank Dr. Mahesh K. Lakshman for his support at the
CCNY, CUNY.
I could have not completed this dissertation without the unlimited support from my family
and friends. I particularly would like to thank my mom, Dr. Barnana Vijaya Kumari, as
well as my dad, Basava Vijaya Bhaskara Rao, and my sister, Shilpa Basava, for
supporting me morally throughout my PhD programme. I would even like to thank Irene,
Kyle, Nada, Sumiea and Emi for their endless support.
![Page 6: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/6.jpg)
5
Table of Contents
Acknowledgements 4
Abstract 7
Chapter 1 Introduction 8
1.1 General Information 8
1.2 Antigen presenting cells (APCs) 10
1.3 Major Histocompatibility Complex 11
1.4 Stimulation of T-cell activation by dendritic cells 13
1.5 Zwitterionic polysaccharides as T-cell dependent antigens 13
1.6 T-cell dependent immune responses: Peritonitis and abscess formation 15
1.7 Bacteroides fragilis 16
1.8 PSA structure 18
1.9 ZPS-mediated CD4+ T-cell activation 18
1.10 Cytokines involved in T-cell-dependent immune responses 19
1.11 Toll-like receptor (TLR) signaling 20
1.12 Aim of the present study 22
Chapter 2 Synthesis and Biological Evaluation of a Potential Immunomodulatory 23
Zwitterionic Polysaccharide
2.1 Introduction 23
2.2 Results and Discussion 37
2.2.1 Synthesis of the pyruvate containing galactose moiety 37
2.2.2 Synthesis of the phthalimido aduct 44
2.2.3 Synthesis of the mono-silylated 1,4-cylcohexanediol 48
2.2.4 Synthesis of the title compound 49
2.2.5 Biological evaluation 51
Chapter 3 Synthesis of Chemical Reactivity of 3,6-Anhydro-D-glucal 56
3.1 General Information 56
3.2 Background 68
3.3 Results 71
3.4 Summary 75
Chapter 4
4.1 Experimental 76
![Page 7: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/7.jpg)
6
4.2 NMR Spectra 93
4.3 References 164
![Page 8: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/8.jpg)
7
ABSTRACT
Synthesis and Evaluation of Biological Activity of a Potential
Immunomodulatory Zwitterionic Polysaccharide
Vikram Basava
Doctor of Philosophy in Chemistry
Seton Hall University
Dr. Cecilia H. Marzabadi
The gram-negative anaerobic bacterium Bacteroides fragilis is an integral component of
the normal gastrointestinal flora. The bacterium colonizes the intestinal tract of human
beings as it has no reservoir other than mammals. An unprecedented proportion of the
genomic DNA of B. fragilus is involved in the production of capsular polysaccharides.
These capsular polysaccharides are important virulence factors in most extracellular
bacterial pathogens. Eight of these polysaccharides have been identified thus far, out of
which two were found to be zwitterionic polymers, PSA1 and PSA2. PSA1 was found to
stimulate T-cell lineage of the immune system because of the dual charge structural
feature of the molecule.
This dissertation discusses about the synthesis of a PSA1 analogue and evaluating its
immunomodulatory activity. Also discussed are the synthesis and the chemical reactivity
of 3,6-anhydro-D-glucal which was formed unexpectedly in the synthesis of L-rhamnal.
![Page 9: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/9.jpg)
8
Chapter 1
Introduction
1.1 General Information
The human immune system utilizes a variety of defense mechanisms to maintain the
integrity of the human body. Recognizing, as well as differentiating between self and
foreign antigens and defending the body from diverse infectious invaders are the major
tasks of the immune system. The defense mechanisms consist of several protective
measures such as natural barriers, non-specific (innate) as well as specific (adaptive)
immune responses. Natural barriers are the first line of defense and are comprised of
both physical, as well as, chemical barriers. Skin, being the toughest layer for a
pathogen to overcome, is a physical barrier. Chemical barriers come into action when
the integrity of the skin is compromised, often due to injury. Each region of the body has
its own strategy and contributes to host defense against pathogens. Mucous
membranes are protected by the secretion of anti-microbial immunoglobulins that can
be found in saliva or tears. Mucous as well as cilia located in lower respiratory tract
prevent colonization from pathogens. Similarly, the acidic pH in the gastrointestinal tract
is an inhospitable environment for most microorganisms.1
The second line of defense is the innate immune system, which acts on the antigens
that penetrated the first line of defense, i.e., the skin and mucous membranes. Antigens
are toxins or other foreign substances that induce an immune response in a body by
producing antibodies. Innate immune responses which are found in all living organisms
![Page 10: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/10.jpg)
9
are antigen independent and act immediately on the clearance of pathogens with a
maximal response. The response is cell mediated and humoral, but, does not generate
a lasting protective immunity because of the lack of immunologic memory.
Microorganisms are detected and destroyed within minutes or hours by the various
mechanisms of the innate immunity and occasionally causing perceptible disease in a
normal, healthy individual.1
The cells of the immune system originate from the stem cell. The stem cells produce
myeloid progenitor cells as well as lymphoid progenitor cells. Myeloid progenitor cells in
the bone marrow give rise to neutrophils, eosinophils, basophils, monocytes and
dendritic cells. The lymphoid progenitor cells give rise to T-cells and B-cells.
Macrophages and dendritic cells, which play a key role in innate and adaptive
immunity, are derived from monocytes. Mast cells, which are fixed in tissues, develop
from the same precursor cell as the circulating basophils. B-cells are produced in the
bone marrow and are released into the blood the lymphatic systems. B-cells can further
develop into plasma cells that secrete antibodies. Precursor T-cells undergo
differentiation in the thymus into two distinct types of T-cells, the CD4+ T-helper cells
and the CD8+ cytotoxic T-cells. Macrophages and dendritic cells function as bridges
between innate immunity and adaptive immunity, since they present antigens to the
immunocompetent T-cells which initiate an immunological response. Phagocytes
involved in the innate immune system are macrophages, mast cells, dendritic cells and
granulocytes. They act upon the antigens by breaking them down with the digestive
enzymes in their lysosomes. Only when an infectious organism breaches these early
lines of defense will an adaptive immune response ensue.1
![Page 11: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/11.jpg)
10
The third line of defense is the adaptive immune system which comprises of the
antigen-specific B-cell and T-cell lymphocytes. T-cells get involved with the B-cells,
which have the ability to rearrange genes of the immunoglobulin family, as soon as the
innate immune system signals the presence of a danger to the T-cells of the adaptive
immune system. This results in the creation of diverse antigen-specific clones and
immunological memory.2 The adaptive immune system then activates antigen-specific
lymphocytes to proliferate and to differentiate into effector and memory cells that
eliminate pathogens. Memory cells can prevent recurrence of disease caused by the
same microbe. This highly sophisticated and potent adaptive immune system needs to
be conducted, instructed and regulated by antigen presenting cells (APCs).
1.2 Antigen Presenting Cells (APCs)
Antigen Presenting Cells (APCs) include dendritic cells (DCs), macrophages as well as
the B-cells. Bone-marrow derived APCs are present on peripheral blood and lymphatic
tissues as well as in other organs to guard the host.1 DCs carry the antigens of the
pathogen to the secondary lymphatic organs, the lymph nodes and the spleen. They
also help in intracellular engulfing and degrading the antigens.
The activity of the DCs depends upon the extent of their maturation. Immature DCs
have a tremendous phagocytic activity to ingest antigens via pinocytosis or receptor-
mediated endocytosis. They have a number of receptors that enhance the uptake of
antigens, and they are specialized to convert these antigens into Major
Histocompatibility Complex (MHC)-peptide complexes that can be recognized by
lymphocytes. Mature DCs lose their phagocytic activity and activate the adaptive
immune system response by transforming into highly-effective APCs which have a very
![Page 12: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/12.jpg)
11
short life span with no proliferation capacity.3 Upon antigen-mediated activation, DCs
influence both the innate and the adaptive immune responses, thereby determining how
the immune system responds to the presence of infectious agents.1
1.3 Antigen processing and Major Histocompatibility Complex (MHC)-dependent
antigen presentation in APCs
Activation of the adaptive immune system by DCs is mediated by cytokine secretion and
by direct presentation of antigens to T-cells. T-cells, which circulate between blood and
peripheral lymphoid tissues, consist of T-helper, T-cytotoxic and T-regulatory cells. The
CD4+ T-helper cells depend on the major histocompatibility complex (MHC) class II
peptide-contact to initiate and modulate receptor- and cytokine-mediated functions of
the immune system.4 CD8+ T-cytotoxic cells depend on the MHC class I by recognizing
the endogenous antigens and mediating the cytotoxic immune system.5 MHC is a
membrane glycoprotein encoded in a cluster of genes. It displays peptide antigen to T-
cells. T-regulatory cells suppress the immune response and protect the host from
aggressive effector mechanisms of the immune system.
Extracellular pathogens and proteins captured by APCs are either recycled to the
plasma membrane or transported to the lysosome for degradation. They are then
presented to the CD4+ T-cells through MHC class II proteins to induce an immune
response.1, 6 Proteases, glycosidases and lipases present in endolysosomes are
activated by low pH giving rise to protein degradation into smaller peptide fragments.
The peptide needs to get loaded onto the MHCII molecule for it to present the antigen to
a CD4+ T-cell.7 The MHCII molecules are present only on the professional APCs, unlike
![Page 13: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/13.jpg)
12
the MHCI molecules. The MHCII molecule complex consists of two transmembrane
glycoproteins, the α and the β, which form a non-covalently bound complex. The open
ends on the peptide-binding groove of the MHCII molecules get filled and blocked when
the invariant chain prevents uncontrolled early binding thereby targeting it to an acidic
endosomal compartment. The activated proteases cleave the MHCII:invariant chain
complex when it enters the acidic endosomal pathway leaving a short fragment called
class II-associated invariant-chain peptide (CLIP). Intracellular antigen loading of MHCII
is dependent on HLA-DM, a MHCII-like molecule in humans (H-2M in mice) which is
found predominantly in the MHCII compartment.8 The antigen first binds to the MHCII
molecule, catalyzes the release of the CLIP fragment from the MHCII binding groove,
stabilizes the MHCII molecule to prevent aggregation and aids in rapid and tight binding
of peptides to the empty MHCII molecule. The MHCII:peptide complex is then
transported from the lysosome to the cell surface and the peptide presented to CD4+ T-
cells.9 Once recognized, the CD4+ T- cells activate other effector cells of the immune
system, like macrophages, which kill the intravesicular pathogens they harbor, or B-cells
to secrete immunoglobulins against the foreign bodies.
The B-cell antigen receptors are a membrane-bound form of antibodies which will be
released upon activation, plasma cell differentiation and proliferation of the B-cell with a
specific antigen. The MHCII:peptide complex must be stable at the cell surface. If it isn’t
stable, the pathogen in the infected cell could escape detection or be picked by MHC
molecules of an infected cell and be wrongfully destructed by cytotoxic T-cells.1
There are about 30,000 antigen-receptor molecules, called T-cell receptors (TCRs) on
the T-cells which consist of TCRα and TCRβ polypeptide chains linked by a disulfide
![Page 14: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/14.jpg)
13
bond. The TCR on the cell surface recognizes processed and presented peptide
antigens. The α:β heterodimers have a similar structure to the Fab fragment of an
immunoglobulin molecule which account for antigen recognition by most T-cells.1
1.4 Stimulation of T-cell activation by Dendritic cells (DCs)
An immunological synapse made up of MHCII:peptide complexes on the DC and the
TCR on the T-cells is formed when the mature DCs interact with the T-cells. This
interaction leads to the activation of the T-cells by an intracellular signaling pathway
which leads to the induction of differentiation and proliferation. The naïve T-cells
proliferate and their progeny adhering to the APCs develop into armed effector T-cells.1
The secretion of cytokines leads to the DCs further directing T-cell development
towards Th1 and Th2 phenotypes via cytokine production.10 Interaction of immature or
tolerogenic DCs with T-cells can result in T-cell deletion, anergy, or the generation of
Treg cells.11
1.5 Zwitterionic polysaccharides as T-cell-dependent antigens
MHCII proteins were previously only known to present proteins, peptides or
superantigens. Most of the known bacterial polysaccharides do not get processed or
presented on the APC surface to T-cells, as they fall apart in the lysosomes of the
APCs.6 But, recent in vivo and in vitro studies showed that some polysaccharides of
certain symbiotic bacteria get transported from lysosomes to the cell surface to get
presented by MHCII protein. This results in the activation of CD4+ T-cells in vitro and the
induction of CD4+ T-cell-dependent abscesses in vivo.12,13,14,15,16 Hence, this discovery
of the MHCII pathway being responsible for carbohydrate antigen presentation and
![Page 15: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/15.jpg)
14
eventual T-cell recognition alters the previous fundamental model of MHCII-antigen
binding.
The CD4+ T-cell activation by bacterial polysaccharides is dependent on the transport of
bacterial polysaccharides via MHCII. The functional role of HLA-DM is to help the
bacterial polysaccharide to compete with peptides for MHCII binding.13,14
The few polysaccharides which induce the CD4+ T-cell-dependent formation of
abscesses in vivo are characterized by the presence of opposite charged motifs on
each repeating unit. They are therefore termed as zwitterionic polysaccharides (ZPS).
They include polysaccharides like PS A1 and PS A2, Sp1, and CP5 from the
commensal bacteria Bacteroides fragilis, Streptococcus pneumonia and
Staphylococcus aureus, respectively (Fig. 1.1).17 The presence of zwitterionic charges
is critical for the antigenic function of the ZPSs. Removal of either of the charges on the
ZPS resulted in compounds that failed to stimulate CD4+ T-cells.18
![Page 16: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/16.jpg)
15
Fig. 1.1: Subunits of PSA1, PSA2, Sp1 and CP5
1.6 T-cell-dependent immune responses: Peritonitis and abscess formation
Secondary peritonitis, the most common one, is observed because of the loss of
integrity in the gastrointestinal tract. This is due to the contamination of the peritoneal
space by symbiotic intestinal bacteria.19 Development of intraperitoneal abscesses, a
bacterial infection, is followed by colonic leakage of commensal intestinal bacteria. It is
seen in patients with inflammatory bowel diseases (IBD) like Crohn’s disease or
ulcerative colitis. Almost a third of patients infected with general peritonitis die in spite of
improved diagnostic modalities, potent antibiotics, modern intensive care and
aggressive surgical treatment.20 The surgical treatment for generalized peritonitis is
through peritoneal lavage, drainage of localized abscesses, removal of the
contaminating source by repairing, and drainage of the peritoneal cavity. However, even
in the presence of improvised therapy, residual abscesses form in patients resulting in
substantial morbidity and mortality.21
Abscess formation is known to be a CD4+ T-cell-dependent immune response induced
by ZPS.18 The zwitterionic charge promotes CD4+ T-cell-dependent abscess induction
![Page 17: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/17.jpg)
16
in experimental murine and rat models.22 Chemical abrogation of the zwitterionic charge
demonstrated that the charged nature of ZPS is critical for its ability to induce abscess
formation. No CD4+ T-cell-dependent immune responses are observed for ZPS
derivatives that have been made neutral or only possess a single charge (cation or
anion).18 In contrast, uncharged polysaccharides induce T-cell-dependent immune
responses after they are modified to possess a zwitterionic charge.18,23,24
1.7 Bacteroides fragilis
Bacteroides fragilis is a Gram-negative, anaerobic, bile-resistant, non-spore forming,
rod-shaped bacterium whose primary known environmental reservoir is the human
lower gastrointestinal tract where it lives as a commensal organism. They are significant
clinical pathogens and are found in most anaerobic infections, with an associated
mortality of more than 19%. The bacteria maintain a complex and generally beneficial
relationship with the host when retained in the gut. They fermentation of carbohydrates
in the human intestine results in the formation of a pool of volatile fatty acids which are
reabsorbed through the intestine and utilized by the host as an energy source.25 But,
when they escape from the gut, they can cause significant pathology including
bacteremia and abscess formation in multiple body sites. Though B. fragilis accounts for
only 0.5% of the human colonic flora, it is the most commonly isolated anaerobic
pathogen because of its potent virulence factors. They have the most antibiotic
resistance mechanisms and the highest resistance rates of all anaerobic pathogens.
Clinically, Bacteroides sp. have exhibited increasing resistance to many antibiotics
including cefoxitin, clindamycin, metronidazole, carbapenems and fluoroquinolines (e.g.,
gatifloxacin, levofloxacin and moxifloxacin).
![Page 18: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/18.jpg)
17
A distinctive feature of B. fragilis is the large proportion of the genome devoted to
carbohydrate metabolism, including the degradation of dietary polysaccharides and the
production of surface polysaccharides.26,27,28 The ability to express multiple capsular
polysaccharides has been shown to enhance intestinal colonization by B. fragilis.29 Thus
far, eight different capsular polysaccharides, each synthesized from different genomic
loci, have been identified. Two of the capsular polysaccharides of B-fragilis,
polysaccharide A (PSA) and polysaccharide B (PSB) belong to a class of carbohydrates
known as zwitterionic polysaccharides (ZPSs). Previously, carbohydrates had been
characterized as classic T-cell-independent antigens that induce a specific IgM
response but fail to evoke an IgG or memory response.30,31 However, it is now known
that ZPSs are capable of inducing CD4+ T-cell-dependent immune responses. All of the
known ZPSs have immunomodulatory properties that depend on the presence of both
positively and negatively charged groups within the repeating units.18,22,32 Of all the
known ZPSs, PSA is the best characterized.
PSA is a unique and potent antigen. Among carbohydrates, this polysaccharide stands
out as a T-cell dependent rather than a T-cell-independent antigen. Although it is
processed and presented along the same pathways as conventional peptide antigens,
PSA modulates the host immune system more extensively than many other known T-
cell-dependent antigens.
![Page 19: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/19.jpg)
18
1.8 PSA Structure
Fig 1.2: Structure of Polysaccharide A (PSA)
PSA is a zwitterionic polysaccharide, with an average molecular mass of 100 kDa,
comprising of repeating tetrasaccharide units. The positive charge is situated at the free
amino group of the rare 2-acetamido-4-aminofucose moiety and the negative charge
resides on the carboxylate of the pyruvate ketal spanning C4 and C6 in the
galactopyranosyl residue.
1.9 ZPS-mediated CD4+ T-cell activation
Activation of CD4+ T-cells requires the specific interaction of the α-β T-cell receptor
(TCR) on the T-cell with the antigen presented in the context of MHCII on a professional
APC.33 To induce an immune response, PSA must be processed in an endocytic
pathway and presented on an MHCII molecule in a manner analogous to that by which
peptide antigens are presented. The notable difference is that, in the endosome, the
degradation of PSA to a molecule size small enough for presentation by the MHCII
![Page 20: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/20.jpg)
19
molecule is a non-enzymatic chemical process. Whereas, protein degradation occurs
enzymatically.33,34 Once taken up into an APC, PSA follows the same processing
pathway as peptide antigens. Upon entry into the endosome of an APC, PSA is directed
to a MHCII compartment. The up-regulation of inducible nitric oxide synthetase, which is
associated with the oxidative burst, results in increased nitric oxide (NO) production. NO
breaks down PSA through deamination, a chemical reaction in which PSA is oxidized
and then depolymerized to a much smaller molecular size while retaining the
zwitterionic motif and the overall structure of the repeating unit. Finally, co-localization of
PSA, MHCII, and α-β TCRs can be detected on the cell surface of murine splenocytes
by confocal microscopy. However, no PSA is found on the cells lacking MHCII.34 In the
absence of direct contact between APCs and T-cells, ZPSs cannot stimulate T-cell
proliferation or induce cytokine production in vitro.16
1.10 Cytokines involved in T-cell-dependent immune responses
Cytokines are of great importance in CD4+ T-cell-induced abscess formation. It has
been suggested that cytokines may be responsible for triggering the migration of
immune cells into the peritoneal cavity following contamination with B. fragilis.35
Cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), IL-6, IL-12, IL-
15 and IL-18 are involved in T-cell activation as well as proliferation.36 It was
demonstrated that ZPS PSA induces the production of TNF-α and IL-1α on peritoneal
cells which act as significant immune mediators for abscess formation.37 When TNF-α is
blocked, expression of the ICAM-1 (intercellular adhesion molecule-1) is significantly
reduced leading to the accumulation of polymorphonuclear leukocytes (PMNLs) within
the abdominal cavity. This then inhibits the formation of a peritoneal sepsis.
![Page 21: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/21.jpg)
20
Furthermore, PSA stimulates the secretion of chemokines such as IL-8 which stimulate
T-cells.
IL-10, one of the most potent anti-inflammatory cytokines in the immune system, is
required for PSA suppression of the inflammatory immune response. It plays a critical
role in protection against inflammation in several animal models.
During sepsis and peritonitis, IL-6 is considered as an import mediator of immunologic
alterations in the host, along with TNF-α and IL-1.38 From the results observed, IL-6 is
the most potent proinflammatory cytokines because it stimulates the expression of the
broadest spectrum of acute phase proteins in inflammation and infection.39
IL-6 is a pleiotropic inflammatory cytokine which is produced by a variety of cells. It acts
on a wide range of tissues by stimulating the activation, survival and proliferation of
CD4+ T-cells and acts on T-cells as an anti-apoptotic factor.40 IL-6 prevents apoptosis of
normal and resting T-cells in the absence of additional cytokines. It has also been
identified as a migration factor for human primary T-cells.41 In vitro experiments showed
chemotactic activity of IL-6 on peripheral blood lymphocytes, lymphokine-activated killer
cells, and CD4+ and CD8+ T-lymphocytes.42 IL-6 was also found to be linked to T-cell-
dependent immune diseases and autoimmune diseases such as the inflammatory
bowel diseases, ulcerative colitis and Crohn’s disease.43
1.11 Toll-like receptor (TLR) signaling
Toll-like receptors (TLRs) are a class of proteins that play a key role in the innate
immune system. They are single, membrane spanning, non-catalytic receptors usually
expressed in cells such as macrophages and dendritic cells. TLRs play a critical role in
![Page 22: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/22.jpg)
21
host defense by sensing the presence of microbes. They mediate inflammatory
responses, coordinate innate and adaptive immunity, prime naïve T-cells, and induce
memory to facilitate the elimination of pathogens, upon activation.44,45 The TLRs include
TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, TLR11, TLR12,
and TLR13. TLR12 and TLR13 are not found in humans. TLRs recognize certain highly
conserved microbial components known as pathogen-associated molecular patterns
(PAMPs). They even recognize other molecules like bacterial lipopolysaccharides,
flagellin, bacterial DNA, and viral double-stranded RNA.46 Nevertheless, both
pathogenic and commensal microbes produce the microbial ligands which are
recognized by TLRs. Although TLR signaling was traditionally associated with the
sensing of the pathogens, it is now appreciated that commensal bacteria are also
recognized by TLRs, and that this interaction is critical for protection against epithelial
injury and intestinal homeostasis.47
The triggering of TLRs on DCs leads to the induction of co-stimulatory signals (e.g.
MHCII) and to the production of cytokines that orchestrate T-cell recruitment, activation,
differentiation and survival and are essential for the induction of adaptive immune
responses.48 Likewise, the decrease in processing and presentation of PSA combined
with the decreased production of IL-12 by dendritic cells activated by PSA in the
absence of TLR2 signaling demonstrates that in addition to the stimulation of a specific
CD4+ T-cell immune response, innate immune pathways are required for PSA to
establish a Th1/Th2 balance.
![Page 23: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/23.jpg)
22
1.12 Aim of the present study
From what was discussed above, it is quite evident that ZPSs like PSA have the
potential to induce CD4+ T-cell-dependent immune responses in vitro and are also
capable of inducing abscess formation in vivo in a CD4+ T-cell-dependent manner. But,
not much work has been done to date to study the potential to induce CD4+ T-cell-
dependent immune responses of simplified, zwitterionic polysaccharides which are
analogous to PSA.
We propose to study the synthesis of an immunomodulatory zwitterionic polysaccharide
as well as its interactions with APCs and T-cells. The molecule synthesized will be
evaluated for its ability to produce IL-6 and TNF-α in APCs. IFN-γ (T-cell response) and
IgM (B-cell response) production will be studied using mouse spleen cells in co-culture
with APCs. Finally, a cell proliferation assay will be done on the spleen cells of mouse.
The initiation of both innate and adaptive responses by the ligands could prove to be a
major step forward in the development of a carbohydrate-based vaccine.49
![Page 24: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/24.jpg)
23
Chapter 2
Synthesis and Biological Evaluation of a Potential Immunomodulatory
Zwitterionic Polysaccharide
2.1 General Information
A considerable amount of work has been done for the synthesis of various zwitterionic
molecules. The compounds synthesized were found to be of incredible importance in
the field of science. Kowalczky50 reported the synthesis of alkylammonium zwitterionic
amino acid derivatives (Fig 2.1). The molecules synthesized were characterized by
FTIR, NMR spectroscopy and DFT calculations. The pharmacotherapeutic potential of
the molecules synthesized was estimated by Prediction of Activity Spectra for
Substances (PASS) which showed that the compounds could be used for as creatinase
inhibitors, polyamine-transporting ATPase inhibitors, hydrogen dehydrogenase
inhibitors and alkylacetylglycero-phosphatase inhibitors. They were even predicted to be
useful as antiviral, antitoxic and antimutagenic agents.
![Page 25: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/25.jpg)
24
Fig. 2.1 Synthesis of 3-(3-dimethylamonio)propylammonio propanoate bromide (a), 4-
(3-dimethylamonio)propylammonio butanoate bromide (b), 5-(3-
dimethylamonio)propylammonio pentanoate bromide (c)
Similarly, Szoka, et al.,51 reported and synthesized a novel class of zwitterionic lipids
with head groups containing a 3o or 4o amine and a carboxylate group. These lipids
were found to form stable liposomes that exhibit head group dependent, pH-responsive
biophysical characteristics which could make them suitable for drug delivery
applications.
Zwitterionic structure monomers such as phoshorylcholine52, sulfobetaine53 and
carboxybetaine54 have been found to reduce protein absorption and platelet adhesion.
Xu, et al.,55 incorporated these charged groups into polyurethanes (Fig 2.2) by
synthesizing them from a polycarbonatediol with alkyne groups and 3-((azidoethyl)
![Page 26: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/26.jpg)
25
dimethylammonio)propane-1-sulfonate using the copper catalyzed 1,3-dipolar
cycloaddition (click) reaction.
Fig. 2.2 Polyurethane
Likewise, Bergstrom56 and others described the synthesis and the structure–activity
relationships of zwitterionic spirocyclic compounds which are used as potent cysteine-
cysteine chemokine receptor-1 (CCR1) antagonists (Fig 2.3). A spirocyclic amine was
treated with 3-bromo-2,2-dimethyl-propan-1-ol in the presence of NaI and Et3N in DMF
to give the desired adduct which upon coupling with 4-fluoro-2-hydroxybenzoate in a
Mitsunobu type reaction gave the ester adduct. The ester adduct was then treated with
the racemate of methyl pyrollidine-3-carboxylate in the presence of carbonyl di-
imidazole (CDI) in N, N-dimethylformamide (DMF) to give a mixture of the
diastereomers.
![Page 27: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/27.jpg)
26
Fig. 2.3 (a) NaI, Et3N, DMF, 78 oC 60 h; (b) methyl 4-fluoro-2-hydroxybenzoate, Ph3P, DEAD, THF, rt 20 h; (c) (R)-methyl pyrrolidine-3-carboxylate/(S)-methyl pyrrolidine-3-carboxylate, CDI, DMF, rt, 20 h
Of the few known zwitterionic capsular polysaccharides, the structures of only a handful
of them (PS A1 and PS A2, Sp1, and CP5 from the commensal bacteria Bacteroides
fragilis, Streptococcus pneumonia and Staphylococcus aureus, respectively) have been
characterized thus far (Fig 2.4).
![Page 28: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/28.jpg)
27
Fig. 2.4 Zwitterionic polysaccharides (Subunits)
Bundle, et al.,57 first synthesized the hexasaccharide representing two repeating units of
the zwitterionic capsular polysaccharide from Streptococcus pneumoniae type 1 (Sp1).
The synthesis involved the stereoselective construction of 1,4-cis-α-galactose linkages
based on a reactive trichloroacetimidate donor that incorporates a 6-O-acetyl group
which has been proposed to account for the α-selectivity in glycosylation.
Later, Codee, et al.,58 came up with a modular approach towards the synthesis of all
possible trimer repeating units of the Sp1 polysaccharide. For efficiently introducing α-
galacturonic acid bonds stereoselectively, galacturonic-[3,6]-lactone building blocks
![Page 29: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/29.jpg)
28
were used. The building blocks not only acted as donor galactosides, but they were also
functional as reactive acceptor glycosides when equipped with a free hydroxyl group
(Fig 2.5).
Fig. 2.5 Three frame-shifted trimer repeats of Sp1 polysaccharide
Similarly, Bundle, et al., were successful in synthesizing a trisaccharide repeat of the
zwitterionic Sp1 polysaccharide. 2-Azido-4-benzylamino-4N,3-O-carbonyl-2,4,6-
trideoxy-D-galactopyranosyl trichloroacetimidate (B), was synthesized in six steps from
6-deoxy-D-glucal. The glucal was glycosylated with selectively protected α-1,3-linked
methyl galabioside (C, D) to produce the trisaccharide skeleton of Sp1 (Fig 2.6).
![Page 30: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/30.jpg)
29
Fig. 2.6 Trisaccharide repeat of zwitterionic Sp1 (A) and the monosaccharide synthons (B, C, D)
PS A1, one of the zwitterionic capsular polysaccharides of Bacteroides fragilis, was first
synthesized successfully by van der Marel, et al.,59 in its fully protected form (Path I, Fig
2.7). One of the drawbacks of this synthesis is that the overall yield was low because of
very low nucleophilicity of molecule B.
Seeberger, et al.,60 later synthesized the same molecule by the [3+1] glycosylation
technique, in its unprotected form (Path II, Fig 2.7). Glycosylation in this process took
place between the highly electro deficient trisaccharide glycosylating agent C, and the
pyruvated galactose nucleophile D. The –OH group on C3 of the galactose residue
acted as a very good nucleophile.
![Page 31: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/31.jpg)
30
Fig. 2.7 Retrosynthesis of PS A1
For the de novo synthesis of the 2-acetamido-2-amino-2,4,6-trideoxy-D-galactose
(AAT), N-Cbz-L-threonine (i) was used as the starting material (Fig 2.8). It was first
converted to a methyl ester followed by acetylation to give (ii). Treatment of (ii) with
lithium bis(trimethylsilylamide) (LHMDS) resulted in a Dieckmann cyclization61, 62 to give
enoate (iii). The treatment of (iii) with 1,2-diisobutylaluminium hydride (DIBAL)63 gave
(iv) which upon reduction under Luche64 conditions gave allylic alcohol (v). Acetylation of
(v) followed by azidonitration65 gave (vii). Cleavage of the anomeric nitrate in (v) with p-
TolSH/DIPEA66 followed by reaction with 2,2,2-triflouroacetamidoyl chloride resulted in
the formation of the N-phenyl trifluoroacetimidate sugar (A).
![Page 32: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/32.jpg)
31
Fig. 2.8 Synthesis of the AAT building block (A)
Reagents and conditions (a) i., FmocCl, py., 0 °C, 79%; ii., BzCl, py., 0 °C, 82%; iii., TsOH, MeOH, 40
°C; iv., CH3C(O)CO2Me, BF3·OEt2, CH3CN, 23 °C, 39%, two steps; (b) i., i-PrOH, NIS, AgOTf, CH2Cl2, 0
°C; ii., NEt3, CH2Cl2, 23 °C, 49%, two steps; (c) LevOH, DIPC, DMAP, CH2Cl2, 0 to 23 °C, 90%; (d) i.,
NIS, THF, H2O, 23 °C; ii., F3CC(NPh)Cl, Cs2CO3, CH2Cl2, 0 °C, 83%, two steps; (e) i., NBS, EtOAc, H2O,
23 °C, 91%; ii., F3CC(NPh)Cl, Cs2CO3, CH2Cl2, 23 °C, 87%
The galactosamine derivative was earlier synthesized (Fig 2.9) by the initial treatment of
(viii) with naphthyl bromide and NaH followed by cleavage of the benzylidene ring with
TES and TFA in CH2Cl2 to give the 6-O-benzylated galactosamine derivative, (ix).67
Fig. 2.9 Synthesis of the galactosamine derivative (ix)
Reagents and conditions (a) NapBr, NaH, THF, 0 oC to 23 oC, 84%; (b) TES, TFA, CH2Cl2, 0 oC to 23 oC, 81%
![Page 33: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/33.jpg)
32
The galactosamine derivative obtained, (ix), was then glycosylated (Fig 2.10) with the
AAT, (A), in the presence of TMSOTf in CH2Cl2 at 0 oC to give the disaccharide (x).
Fig. 2.10 Glycosylation of the AAT building block (x)
Reagents and conditions (a) TMSOTf, CH2Cl2, 0 °C, 74%
Similarly, the galactofuranose building block (xii), was synthesized (Fig 2.11) by
reacting the known thiol68 (xi) with N-bromosuccinimide (NBS) to form the lactol,
followed by the formation of the N-phenyl trifluoroacetimidate derivative (xii).
Fig. 2.11 Synthesis of the galactofuranose building block (xii)
Reagents and conditions (a) i., NBS, EtOAc, H2O, 23 °C, 91%; ii., F3CC(NPh)Cl, Cs2CO3, CH2Cl2, 23
°C, 87%
![Page 34: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/34.jpg)
33
The last building block, the pyruvated galactose sugar (D), was synthesized from the
benzylidene galactoside (xiii).69 The C3 and C2 hydroxyl groups were initially protected
with Fmoc70 and Bz groups respectively (Fig 2.12). Cleavage of the benzylidene acetal
was followed by the formation of the pyruvate ketal71 (xiv) using BF3. OEt2. Finally,
glycosylation of (xiv) with isopropanol in the presence of NIS/AgOTf followed by removal
of the Fmoc protecting group gave the pyruvated galactose nucleophile (D).
Fig. 2.12 Synthesis of the pyruvated galactose nucleophile (D)
Reagents and conditions (a) i., FmocCl, py., 0 °C, 79%; ii., BzCl, py., 0 °C, 82%; iii., TsOH, MeOH, 40
°C; iv., CH3C(O)CO2Me, BF3·OEt2, CH3CN, 23 °C, 39%, two steps; (b) i., i-PrOH, NIS, AgOTf, CH2Cl2, 0
°C; ii., NEt3, CH2Cl2, 23 °C, 49%, two steps
In the synthesis of the trisaccharide (C), the first step involved the removal of the
naphthyl ether group using 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) (Fig
2.13). The resulting alcohol (xvi) was glycosylated with galactofuranose N-phenyl
trifluoroacetimidate (xii) to give the trisaccharide adduct (xvii) as the β-anomer. The
anomeric tert-butyl-dimethylsilyl (TBDMS) group was removed in the presence of
tetrabutylammonium fluoride (TBAF) to give a lactol that upon treatment with 2,2,2-
triflouroacetamidoyl chloride in the presence of Cs2CO3 resulted in the formation of the
N-phenyl trifluoroacetimidate adduct (xviii). Thioethyl glycoside (C) was later synthesized
![Page 35: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/35.jpg)
34
from glycosyl imidate (xviii) by the reaction of the latter with ethanethiol (EtSH) in the
presence of TMSOTf at 0 oC in the presence of 4 Ao molecular sieves.
Fig. 2.13 Synthesis of the trisaccharide, C
Reagents and conditions (a) DDQ, MeOH, CH2Cl2, 23 °C, 86%; (b) TMSOTf, CH2Cl2, −30 °C, 90%; (c) i., TBAF, AcOH, THF, 0 °C; ii., F3CC(NPh)Cl, Cs2CO3, CH2Cl2, 23 °C, 82%, two steps; (d) EtSH, TMSOTf, 4 Ao MS, CH2Cl2, 0 °C, 96%
![Page 36: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/36.jpg)
35
The resulting trisaccharide (C) formed was made to react with pyruvated galactose
moiety (D) in the presence of dimethyl (methylthio) sulfonium triflate (DMTST)72 and
2,4,6-tri-tert-butylpyrimidine (TTBP) at 0 oC to give the totally protected PS A1 adduct
(xix) in 58% yield (Fig 2.14).
Fig. 2.14 Formation of the tetrasaccharide, (xix)
Reagents and conditions (a) dimethyl (methylthio) sulfonium triflate (DMTST), 2,4,6-tri-tert-
butylpyrimidine (TTBP), 4 Ao MS, 0 oC, CH2Cl2
Finally, the azide groups of fully-protected PS A1 (xix) were converted to acetamides
using ethanethioic acid (AcSH) and pyridine (Fig 2.15). Global deprotection of the
acetamide adduct of PS A1 was performed in two different steps. Initially, the compound
was hydrogenated in the presence of Pearlman’s catalyst73 which removed the benzyl
as well as the CBz groups. Next, NaOMe in MeOH/H2O was added dropwise to form the
final PS A1 tetrasaccharide repeating unit in 46% yield.
![Page 37: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/37.jpg)
36
Fig. 2.15 Deprotection and formation of PS A1 tetrasaccharide repeating unit
Reagents and conditions (a) AcSH, py., 23 °C, 67%; (d) i., H2, Pd(OH)2/C, MeOH, 23 °C; ii., THF, then
0.5 M NaOMe in 1:1 MeOH/H2O, 23 °C, 46%, two steps
Earlier studies revealed that peptides synthesized to mimic the zwitterionic charge motif
associated with zwitterionic polysaccharides exhibited biologic properties. Lysine-
aspartic acid (KD) peptides with more than 15 repeating units stimulated CD4+ T-cells
in vitro and gave protection against abscesses induced by bacteria such as Bacteroides
fragilis and Staphylococcus aureus.74
Alterations made in the charge motifs of the zwitterionic polysaccharides were shown to
have either partially or totally removed the stimulatory properties of the sugars.75 It was
![Page 38: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/38.jpg)
37
also proved that the non-charged portions of the saccharide chain are not essential for
the stimulation by PS A1. Modifications made to the non-charged sugars failed to
diminish the production of cytokines.
Discussed hereafter is the synthesis of an analogue of the PS A1 zwitterionic
polysaccharide that could be of utmost importance in investigating its biological activity.
Since only the charged sugar residues have been implicated in binding and processing
of PS A1, the synthesis has been carried out using a commercially-available
cycloalkane diol as the bridging moiety. As the galactofuranose moiety has zero charge
on it, and as it doesn’t contribute to the size of the PS A1 moiety in increasing the
distance between the charges (Calculated: 13 Ao; Observed: 15 Ao), we decided to not
include it in the synthesis of the analogue.
2.2 Results and Discussions
2.2.1 Synthesis of the pyruvate-containing galactose moiety
The synthesis of the pyruvated sugar moiety started with the commercially available β-
D-galactose pentaacetate (1). It was first made to react with 1.2 equivalents of
thiophenol (PhSH) in the presence of BF3.OEt2 to give predominantly the anomeric β-
substituted thiophenol adduct (2) in 97% yield (Scheme 2.1).76
Scheme 2.1 Synthesis of β-thiophenyl-2,3,4,6-tetra-O-acetyl-D-galactopyranose
![Page 39: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/39.jpg)
38
The thiophenyl adduct obtained was then de-acetylated using Zemplen’s conditions to
yield 98% of the galactopyranose sugar (3) in 98% yield (Scheme 2.2).77
Scheme 2.2 De-acetylation using Zemplen’s conditions
A series of reactions were then set up to selectively protect the C4 and C6 hydroxyl
functional groups. The best possible route chosen involved first forming of the 4, 6-O-
benzylidene protecting group. As the benzylidene ring is preferentially six membered,
there is a greater chance of ring formation between the C4 and the C6 hydroxyl groups.
The de-acetylated thiophenyl adduct (3) was treated with benzaldehyde dimethylacetal
in the presence of camphor sulfonic acid in DMF at 65 oC (Scheme 2.3).78 However,
TLC analysis of the reaction mixture showed that under these conditions esentially no
reaction took place. A similar reaction was also carried out using the dimethyl acetal in
the presence of p-toluenesulfonic acid. But, again there was no reactivity observed
when monitoring by TLC.79 Reactions were set up separately with (3) using
benzaldehyde and benzaldehyde dimethyacetal in the presence of pyridinium p-
toluenesulfonic acid. These reactions also did not show the formation of product.
![Page 40: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/40.jpg)
39
X
Scheme 2.3 Various attempts in synthesizing the benzylidene sugar moiety
When the reaction when set up in the presence of ZnI2 and benzaldehyde, none of the
desired product was obtained (Scheme 2.3). But, the same reaction (Scheme 2.4)
when repeated in the presence of ZnCl2 did give the desired benzylidene sugar (4) in
65% yield.80 The formation of product was supported by the 1H NMR spectrum that
showed a singlet at 5.53 ppm which represents the axial hydrogen on the
benzylidene ring.
![Page 41: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/41.jpg)
40
Scheme 2.4 Synthesis of the benzylidene sugar moiety
Compound (4) was subsequently reacted with dibutyltin oxide and benzoyl chloride in
the presence of 4 Ao molecular sieves in toluene to give a mixture of 2-O-benzoyl and 3-
O-benzoyl sugar derivatives (Scheme 2.5). The latter, being the major product, was
easily separated by flash column chromatography yielding 50% of the 3-O-benzoyl
adduct (5a).81
Scheme 2.5 Selective benzoylation using organo tin chemistry
Various attempts were made to protect the hydroxyl group at the C-2 position. A
benzylation reaction was initially carried out by reacting compound (5a) with benzyl
![Page 42: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/42.jpg)
41
chloride in the presence of NaH and 15-crown-5 in DMF (Scheme 2.6).82 As the
reaction failed to occur, the benzylation reaction was attempted by using
benzyltrichloroacetimidate and trifluoromethane sulfonic acid.83 But, again there was no
product formation. Reaction of (5a) with p-nitro-benzyl bromide in the presence of NaH
and DMF did not show the addition of the benzyl group at the C-2 position. Reaction of
p-methoxylbenzyl chloride with (5a) in the presence of NaH and 15-crown-5-ether did
not show the benzylation reaction happening, but instead resulted in debenzoylation
giving (4) as the final product.84 This offside reaction could have occurred because of
the formation of NaOH when NaH reacted with trace amounts of water in the solution.
![Page 43: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/43.jpg)
42
Scheme 2.6 Attempted benzylation reactions at the C-2 hydroxyl group
The reason for the lack of reactivity of the C-2 was likely due to the bulky nature of the
protecting group used and the sterically crowded environment at that position. Hence, a
smaller protecting group was used. A reaction was carried out between (5a) and acetyl
chloride in the presence of triethylamine and N, N-dimethylaminopyridine which resulted
in the formation of the 2-O-acetyl adduct (6) in 69% yield (Scheme 2.7).
![Page 44: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/44.jpg)
43
Scheme 2.7 Successful acetylation at the C-2 position
The next step was to introduce a pyruvate moiety into the sugar. This could be done by
cleaving the benzylidene ring and subsequently introducing the pyruvate functional
group into the sugar. The benzylidene ring can be cleaved in different ways. Depending
on the reagents used, there may form a 4-O-benzyl-6-hydroxy sugar or a 4-hydroxy-6-
O-benzyl sugar. But, for introduction of the pyruvate ring into the sugar, formation of the
4,6-diol is imperative. Therefore, compound (6) was treated with 20% trifluoroacetic acid
in CH2Cl2 to give a 4,6-diol sugar (7a, 45% yield).85 The diol sugar upon treatment with
methyl pyruvate in the presence of BF3-Et2O gave the desired pyruvate sugar (7) in
80% yield (Scheme 2.8).86
![Page 45: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/45.jpg)
44
Scheme 2.8 Addition of the pyruvate group to the sugar moiety
2.2.2 Synthesis of the phthalimido adduct
Various attempts were made in synthesizing the positive charged moiety having the
amino group on it. First, glucosamine was made to react with acetyl chloride which gave
the per-acetylated-2-acetamido α-glucopyranosyl chloride with a very good yield.87 The
product was then reacted with thiophenol in the presence of Et3N in acetonitrile which
gave the desired β-thiophenyl adduct.88 The obtained product showed no reactivity any
further probably because of the formation of the stable oxazoline ring with the
acetamido group at the C-2 position. Attempts in reacting the glucopyranosyl chloride
with 1, 4-cyclohexanediol in the presence of N-iodosuccinimide and Yb(Otf)3 to yield the
desired O-glycoside were not fruitful (Scheme 2.9).89
![Page 46: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/46.jpg)
45
Scheme 2.9 Earlier attempts in synthesizing the thioglycoside
Subsequently, glucosamine first was per-acetylated, and the product was treated with
BF3. Et2O to give the oxazoline derivative. The oxazoline derivative when treated with
thiophenol and camphor sulfonic acid (CSA) showed no reactivity.90 This can be
attributed to the stability of the oxazoline ring. One-pot reaction for the addition of the
thiophenyl moiety to the per-acetylated glucosamine in the presence of BF3. Et2O upon
sonication did give the desired thiophenyl adduct.91 The reaction was found to have not
reached completion (Scheme 2.9).
![Page 47: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/47.jpg)
46
Having observed problems with the 2-acetamido group because of its formation of a
stable oxazoline ring, plans were made to incorporate a phthalimido group as it doesn’t
take part in the neighbouring group participation. Glucosamine HCl was first reacted
with NaOMe in methanol to get glucosamine which was further reacted with phthalic
anhydride in the presence of Et3N.92 The product (8) was then acetylated by reacting it
with acetic anhydride and di-azo-bicyclooctane (DABCO) to give the desired per-
acetylated 2-phthalimido adduct (9) in 30% overall yield (Scheme 2.10).93
Scheme 2.10 Synthesis of the 2-phthalimido adduct
![Page 48: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/48.jpg)
47
The 2-phthalimido adduct (9) was then made to react with thiophenol in the presence of
a mild base, Et3N. TLC of the reaction did not show the formation of the desired
product. This was observed because of the bulkiness of the thiophenol group (Scheme
2.11).
Scheme 2.11 Substitution of thiophenol at the anomeric carbon atom
Therefore, a smaller thiol, like ethanethiol, was chosen as the leaving group. Reaction
of (9) with ethanethiol and BF3. Et2O in anh. CH2Cl2 gave the desired ethanethiol adduct
(10) in 79% yield (Scheme 2.12).94
Scheme 2.12 Substitution of ethanethiol at the anomeric carbon atom
![Page 49: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/49.jpg)
48
2.2.3 Synthesis of the monosilylated 1, 4-cyclohexanediol
Synthesis of the of one mono-protected hydroxyl group of 1, 4-cyclohexanediol
selectively was not as challenging as the synthesis of the other subunits. First, the
cis/trans mixture of 1, 4-cyclohexanediol was reacted with 1.2 equivalents of benzyl
chloride and NaH in anh. DMF which gave a separable cis/trans mixture of mono-
benzylated product (11a, 11b) with an overall yield of 88% (Scheme 2.13).
Scheme 2.13 Synthesis of the mono-benzylated adduct of 1, 4-cyclohexanediol
But, from the earlier experiences, it was quite evident that debenzylation occurs when
the reactions were carried out at elevated temperatures. Hence, attempts were made in
substituting the benzyl group with a more robust silyl moiety. Reaction of 1, 4-
cyclohexanediol with 1.2 equivalents of tert-butyldimethylsilyl chloride and imidazole in
anh. DMF gave the desired mono-silylated product (12a, 12b) in 50% yield as a white
fluffy solid (Scheme 2.14).95
![Page 50: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/50.jpg)
49
Scheme 2.14 Synthesis of the mono-silylated adduct of 1, 4-cyclohexanediol
2.2.4 Synthesis of the final product
Addition of thioethyl-2-phthalimido-3,4,6-tri-O-acetyl-β-D-glucopyranose (10) to the cis-
mono-silylated adduct of 1,4-cyclohexanediol (12a) in the presence of trimethylsilyl
trifluoromethanesulfonate (TMSOTf) and NIS in CH2Cl2 at -78 oC gave the desired
product (13) in 1.5 h. The same reaction when allowed to warm up to room temperature
gave the desilylated product (14) in 7 h (Scheme 2.15).96
![Page 51: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/51.jpg)
50
Scheme 2.16 Reaction of compound (10) with (12) in the presence of TMSOTf and NIS
Further reaction (Scheme 2.17) of the product (14) with the earlier obtained pyruvate
adduct (7) in the presence of TMSOTf and NIS at -40 oC gave the final desired
polysaccharide subunit (15). As the yields were incredibly low, no further steps were
taken in deprotecting the final compound, and the obtained product was sent for
biological evaluation.
![Page 52: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/52.jpg)
51
Scheme 2.17 Synthesis of the PSA1 analogue
2.3 Biological evaluation
The protected PSA1 analogue (15) was evaluated using ELISA assays for the
production of proinflammatory cytokines TNF-α and IL-6 (innate immunity). The cells
used were the RAW 264.7 and the mouse peritoneal macrophages (C57, BL/6, Jackson
Laboratories, Maine, US). Initial results showed (Fig. 16) that the cytokines produced by
15 were negligible in comparison to those produced by the lipopolysaccharides, when
analyzed on the RAW264.7 and the mouse peritoneal macrophages.
![Page 53: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/53.jpg)
52
Fig. 16 Innate Immunity: Production of TNFα and IL-6 by RAW264.7 and the mouse peritoneal
macrophages
The compound (15) was further evaluated for adaptive immune responses on the
spleen cells. The responses which were analyzed were for the T- and B-cell
proliferation, levels of INF-γ in the supernatants which indicates a T-cell response, and
polyclonal IgM and IgG levels in the supernatants which signifies a B-cell response. It
was found that neither the T-cell nor the B-cell responses were observed with (15).
![Page 54: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/54.jpg)
53
To elucidate the toll like receptor responsible for cytokine production, the peritoneal
macrophages from TLR2 and TLR4 knockout mice (female, 4-6 weeks old, C57BL/6)
were obtained. The cells were cultured with variable concentrations of the compound
(15) and, the TNF-α and IL-6 levels in the supernatants were measured at different time
points (Fig. 17).
Fig. 17 Innate Immunity: Production of TNFα and IL-6 by the peritoneal macrophages from TLR2 and
TLR4 knockout mice
![Page 55: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/55.jpg)
54
It was observed that the production of both TNF-α and IL-6 was reduced in only the
TLR4 knockout mice suggesting that signaling of (15) occurs only through TLR4.
Furthermore, the graphical representation showed that the magnitude of TLR4 signaling
with (15) was greater than the known TLR4 agonist, E. coli LPS (lipopolysaccharide).
Similarly, the extent of binding of compound (15) to the TLR4 receptors was illustrated
by treating the peritoneal exudate cells (PECs) with different concentrations of the
compound. The cells were pre-incubated with the compound, after which they were
washed. To the washed cells were then added the antibody followed by the
phytoerythrin dye (PE) and, the number of the PE positive cells was observed by flow
cytometry (Fig. 18).
![Page 56: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/56.jpg)
55
PECs
contr
ol
g/ml
1
g/ml
5
g/ml
10
0
20
40
60
80
N.S.***
% T
LR
-4 e
xp
res
sio
n
Fig. 18 Results from flow cytometry
The graphs in the figure above show that the increase in the concentration of the
compound (15) results in an increased binding of the TLR-4 receptors to the compound.
The graphs with TLR-2 show that the presence of the compound (15) doesn’t interfere
with the cell count. This clearly depicts that the PSA1 analogue doesn’t bind to the TLR-
2 receptors.
![Page 57: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/57.jpg)
56
Chapter 3
Synthesis and Chemical Reactivity of 3,6-Anhydro-D-glucal
3.1 General Information
Anhydrosugars (or intramolecular anhydrides) are the derivatives of monosaccharides
obtained by the intramolecular elimination of a water molecule resulting in the formation
of a new three-, four-, five-, six- or seven-membered heterocyclic rings. Their advantage
of easy removal has led to the development of numerous derivatives, the synthesis and
properties of which are described in the literature.97, 98, 99, 100, 101 These anhydrosugars
are an important class of sugars which are used for the preparation of modified
carbohydrates including the C-glycosides102, nucleosides103 and heterocyclic
compounds104. They are also used in the synthesis of complex enantiomerically pure
products where in the chirality of the parent sugar is transferred to the target via the
chiron approach.105 They constitute very versatile starting materials not only in
carbohydrate chemistry but also for the synthesis of non-carbohydrate and non-natural
products. Anhydrosugars are the suitable monomers for preparing stereoregular
polysaccharides and their specifically substituted derivatives.1
For the synthesis of the anhydro skeleton in a normal sugar molecule, one of the
hydroxyl groups of the diol which is taking part in the anhydro ring formation is
converted into a leaving group such as a halogen, tosylate or triflate. The other hydroxyl
group acts as a nucleophile resulting in the formation of the anhydro ring by an
intramolecular SN2 approach (Fig. 3.1).
![Page 58: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/58.jpg)
57
Formation of the anhydrosugar by elimination of the water molecule
Mechanism for the formation of the anhydrosugar
Fig. 3.1 Synthesis of anhydrosugar
The reaction protocols proposed by Mitsunobu106 and Castro107 for the synthesis of the
anhydrosugars involve activation of the hydroxyl groups under milder conditions (Fig.
3.2).
Fig. 3.2 Proposed protocols of Mitsunobu and Castro
![Page 59: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/59.jpg)
58
The formation of anhydrosugars, may involve various carbon atoms of the sugar, thus
leading to their categorization into different classes. They are divided into two main
categories: 1. the anhydrosugars which involve the participation of the anomeric carbon
atom, called glycosanes, which resemble the intramolecular glycosides; 2. the
anhydrosugars which do not involve the anomeric carbon atom, called simply as
anhydrosugars.1, 108, 109 The latter group comprises of purely synthetic materials which
are exclusively used in synthetic carbohydrate chemistry.
Classification of the anhydrosugars is also based on the heterocyclic ring formed upon
dehydration. Oxirane (sugar epoxide), oxetane (oxacyclobutane), oxolane
(tetrahydrofuran) and oxane (tetrahydropyran) are the various heterocyclic anhydrides
known. Oxirane and oxetane rings show higher reactivity, whereas oxane and oxolane
rings show comparatively low reactivity. The position of the anhydro ring, the steric
arrangement as well as the conformation of the molecule also play a major role in
determining the reactivity of the heterocyclic anhydrides.
3.1.1 Glycosanes
Compounds which are formed by the dehydration of the anomeric hydroxyl group and
the terminal alcohol of a sugar molecule (1,6-anhydropyranoses, 1,6-anhydrofuranoses)
or with any other alcohol on the sugar ring (1,2-, 1,3-, 1,4-anhydrosugars, etc) come
under the class of anomeric anhydrosugars or glycosanes. The most common of these
are the 1,6- and 1,2-anhydrosugars, while the others are less commonly seen in
carbohydrate chemistry. They resemble conventional glycosides in their sensitivity to
![Page 60: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/60.jpg)
59
acids by undergoing acid hydrolysis. But, highly strained anhydrosugars tend to
undergo hydrolysis even in alkaline solutions.
The formation of the carbocation at the anomeric carbon atom controls the
regioselectivity of the opening of the ring.110 Nucleophilic attack occurs preferentially at
the anomeric carbon atom resulting in the formation of various glycosyl derivatives or
glycosides. The anhydrosugars act as monomers in polymerization reactions to form
stereoregular polysaccharides, as the configuration of the corresponding anomeric, as
well as the nonanomeric carbon atoms, remain the same.
3.1.1.1 1,2-Anhydroaldoses
1,2-Anhydroaldopyranoses have the 2,7-dioxabicyclo[4.1.0]heptanes skeleton which
preferentially adopts 4H5 and 5H4 conformations.111,112 1,2-anhydrohexofuranoses have
the more flexible 2,6-dioxabicyclo[3.1.0]hexane skeleton which adopts an E
conformation. (Fig. 3.3).
Fig. 3.3 1,2-Anhydroaldoses
Brigl was the first to synthesize the 1,2-anhydrosugar (Fig. 3.4).113 1,2-anhydro-3,4,6-tri-
O-acetyl-α-D-glucopyranose or ‘Brigl’s anhydride’ was prepared from β-D-glucopyranose
pentaacetate by sequential treatment with PCl5 and NH3.114 The product was used in
the synthesis of glycosides115 and α-D-linked disaccharides, like sucrose.116
![Page 61: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/61.jpg)
60
Fig. 3.4 Synthesis of Brigl’s anhydride
Subsequently, Danishefsky’s research group synthesized the 1,2-anhydrosugar by
treating a glycal with dimethyldioxirane (Fig. 3.5).117 The product obtained upon
treatment with a nucleophile gave the 2-hydroxy-β-D-glycoside.
Fig. 3.5 Synthesis of 1,2-anhydride using dimethyldioxirane
Similarly, Marzabadi, et al. synthesized the 1,2-anhydro glucal by making a halohydrin
undergo a base induced cyclization (Fig. 3.6).118 Many other 1,2-anhydrides were
synthesized later on.
Fig. 3.6 Synthesis of 1,2-anhydride from a halohydrin
![Page 62: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/62.jpg)
61
3.1.1.2 1,3-Anhydroaldoses
1,3-Anhydrosugars have the 2,6-dioxabicyclo[3.1.1]heptane skeleton and may adopt the
5C2, B2,5 or E2 conformation of the pyranose ring. The presence of axial substituents at
C-2, C-4 and C-5 positions destabilize the 5C2 conformation (Fig. 3.7). The oxetane ring
of 1,3-anhydrosugars is less reactive towards acids in comparison to the sensitivity of
the oxirane ring in both acidic, as well as, in alkaline aqueous solutions.
Fig. 3.7 1,3-Anhydroaldoses
Many of the 1,3-anhydrohexopyranoses of gluco-,119, 120 manno-,121, 122 galacto-,123 talo-
,124 and 6-deoxy derivatives125, 126, 127 were earlier synthesized via analogous
procedures. They were obtained by reacting partially-protected glycosyl halides with
strong bases like NaH and potassium tert-butoxide (Fig. 3.8).
Fig. 3.8 Synthesis of a 1,3-anhydrohexose derivative
![Page 63: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/63.jpg)
62
3.1.1.3 1,4-Anhydroaldoses
The 1,4-anhydroaldoses have the 2,7-dioxabicyclo[2.2.1]heptane skeleton and adopt
two non-interconvertible conformations, B1,4 and 1,4B (Fig. 3.9). They tend to be very
stable in alkaline conditions, but get readily hydrolyzed in the presence of acids. The
synthesis is similar to that of 1,3-anhydrosugars, and many compounds in the D-
gluco,128, 129, 130 D-galacto,131, 132 6-deoxy-L-manno, L-talo,133 L-arabino, D-ribo, D-xylo
and D-lyxo configurations have been synthesized.134, 135, 136, 137, 138
Fig. 3.9 1,4-Anhydroaldoses
3.1.1.4 1,6-Anhydroaldoses
These compounds have the 6,8-dioxabicyclo[3.2.1]octane skeleton and have limited
steric flexibility. Most of them adopt themselves to 1C4 conformation, while some of them
are more flattened in B3,0 conformation. An inversion in the orientation at all the
stereocenters is observed in comparison to the 4C1(D) and 1C4(L) conformations of the
parent compounds. These anhydrosugars resemble methyl β-D-hexopyranosides in
their chemical activity. They are very stable in alkaline conditions, but are very sensitive
to acids (Fig. 3.10).
![Page 64: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/64.jpg)
63
Fig. 3.10 1,6-Anhydroaldoses
Their synthesis includes cyclization of the hexopyranosyl derivatives having a good
leaving group like halides, azides,139, 140, 141 tosylates142 or 2,4,6-trimethylbenzoates143
at the C-1 position and alkali-sensitive glycosides, like phenyl glycosides,144, 145 by the
action of strong bases.
3.1.2 Anhydrosugars
Compounds which are formed by the dehydration of any two hydroxyl groups on the
sugar molecule, other than the hydroxyl group on the anomeric carbon atom, are the
anhydrosugars. These heterocyclic anhydrides include the oxirane (sugar epoxides, 3-
membered), oxetane (oxacyclobutane, 4-membered), oxolane (tetrahydrofuran, 5-
membered) and oxane (tetrahydropyran, 6-membered) derivatives.
3.1.2.1 Oxirane
Oxiranes are the anhydro sugars having a fused oxirane ring to a pyranose or a
furanose moiety. These have the 3,7-dioxabicyclo[4.1.0]heptane and 3,6-
dioxabicyclo[3.1.0]hexane basic skeletons that adopt either 5H0 or 1H0 conformations in
![Page 65: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/65.jpg)
64
the ground state (Fig. 3.11). Generally the 2,3- and 3,4-anhydrohexopyranoses adopt
the flexible half-chair conformation (H) depending on the presence or the absence of
additional fused rings.
Fig. 3.11 Oxiranes
Though there exist many synthetic procedures for oxiranes, the most common
procedure followed is the intramolecular SN2 nucleophilic displacement reaction.
Usually, a tosyloxy or a mesyloxy group gets displaced by a vicinyl hydroxyl group that
has been deprotonated by a base such as sodium methoxide.146, 147, 148
These epoxy sugars are generally used in the synthesis of various derivatives of sugars
like halo-, amino-, thio-, azido-, deoxy- and branched-chain derivatives. The oxirane
ring, which is more reactive than oxetane and oxolane rings, opens in the presence of
nucleophiles both in acidic and in basic conditions. But, it tends to be stable to catalytic
debenzylation reactions (only palladium), in acylations and alkylations in basic media,
and in detosylation reactions in the presence of nucleophiles.
![Page 66: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/66.jpg)
65
3.1.2.2 Oxetane
Anhydrosugars containing a fused oxetane ring in the 2,6-dioxabicyclo[3.2.0]heptane or
the 2,7-dioxabicyclo[4.2.0]octane skeleton are called oxetanes (Fig. 3.12).
Fig. 3.12 Oxetanes
3.1.2.3 Oxolane
These include the bicyclic 2,5-anhydro- as well as the 3,6-anhydro-aldose derivatives.
Their general skeleton is either 2,5-dioxabicyclo[2.2.1]heptane, 2,6-
dioxabicylco[3.2.1]octane or 2,6-dioxabicyclo[3.3.0]octane (Fig. 3.13). They exist even
as monocyclic oxolane derivatives possessing a free aldehyde group. As they are quite
stable in acidic and basic conditions, reactivity of these anhydrosugars is dependent on
the presence or the absence of a free aldehyde group.
![Page 67: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/67.jpg)
66
Fig. 3.13 Oxolanes
From the conformational analysis, it can be inferred that the relatively strained 2,6-
dioxabicylco[3.2.1]octane skeletons of 3,6-anhydro-D-gluco- and –D-manno-pyranose
tend to rapidly recyclize into the less strained 2,6-dioxabicyclo[3.3.0]octane skeletons of
the 3,6-anhydrohexofuranose in the presence of methanolic HCl. Such a rearrangement
was not observed in the galacto- and talo- configurations.149, 150
Many 2,5-anhydropentoses have been described so far, of L-arabino,151 D-lyxo, D-ribo
and D-xylo sugars.152 Chitose or 2,5-anhydro-D-mannose is the most common 2,5-
anhydrohexose derivative.153, 154, 155 It can be prepared by the deamination of 2-amino-
2-deoxy-D-glucose. Other isomers include the derivatives of D-allose,156, 157 D-altrose, L-
idose,158, 159 D-glucose160, 161 and L-talose162.
Among oxolanes, 3,6-anhydroaldohexose derivatives form the major class. As per the
configuration and conformation of all the eight possible 3,6-anhydroaldohexoses
described, some of them exist as bicyclic pyranose, while others exist as bicyclic
![Page 68: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/68.jpg)
67
furanose forms.163, 164 Hence, 3,6-anhydro derivatives of glucose and mannose adopt
both the pyranose and the cis-fused forms, while those of galactose and talose adopt
the pyranose form only. Gulose and idose can adopt only the cis-fused form. Likewise,
free 3,6-anhydro-D-allose and –D-altrose can only exist in the acyclic form.165, 166
3.1.2.4 Oxane
Pyranose and furanose derivatives adopting either the rigid 2,5-
dioxabicyclo[2.2.2]octane skeleton with the pyranose ring in 2,5B or B2,5 conformation or
the less flexible 2,6-dioxabicyclo[3.2.1]octane skeleton in 4C0 conformation are
categorized as oxanes (Fig. 3.14). They comprise of 2,6-anhydrohexoses and 1,5-
anhydroketoses. Among the 2,6-anhydrohexoses, pyranoid derivatives in configurations
of altro,167 ido,168 manno169 and talo170 configurations have been reported. Of the
furanose derivatives, 2,6-anhydro-D-mannofuranose and its derivatives are known.171
Fig. 3.14 Oxanes
They can be synthesized by the reaction of sodium methoxide on the corresponding 6-
tosylate sugar (Fig. 3.15).172 1,5-anhydro-D-fructose is one of the 1,5-anhydroketose
![Page 69: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/69.jpg)
68
sugars which is of particular interest.173 It is the central intermediate formed in the
alternative glycogen catabolic pathway, also called as the Anhydrofructose (AF)
pathway.174
Fig. 3.15 Synthesis of a 2,6-anhydropyranose derivative
3.2 Background
The most widely known compounds from the tetrahedral class of anhydrosugars are
3,6-anhydrofuranoses.175 Furanodictine A and B [Fig. 3.16] are good examples of this
class that show neuronal differentiation activity.176 3,6-Anhydro-D- and L-galactoses and
their partially methylated derivatives are typical constituents of polysaccharides of red
algae.177 3,6-Anhydro sugars forming bicyclic nucleosides have shown antiviral
activity.178 The puckering in the bicyclic carbohydrate moiety is believed to cause the
molecule to be locked in the proper conformation for biological activity to be
observed.179, 180
![Page 70: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/70.jpg)
69
Fig. 3.16 3,6-Anhydrofuranoses
3,6-anhydrohexoses are considered to be of more importance as they are used to
synthesize new nucleoside analogues.181 Reinhold et al. (1974) first synthesized 3,6-
anhydrohexose sugars by selective tosylation at the C-6 carbon atom followed by
treatment of the intermediate tosylates with a strong base (sodium methoxide) (Fig.
3.17). 182 Kreimeier et al. and Gross et al. substituted the hydroxyl group at C-6 by
(Me2N)3P and halogens, upon which the tosylated sugars were treated with a strong
base, as mentioned earlier.183, 184 Liptak et al. later confirmed that the presence of
benzyloxy and methoxy groups at the C-3 position would help in the formation of the
3,6-anhydride bond as they act as good internal nucleophiles. 185
Fig. 3.17 Synthesis of 3,6-anhydropyranose
Similarly, Shibayama, et al. and Santoyo-Gonzales et al. described the synthesis of 3,6-
anhydrohexofuranose derivatives by the basic solvolysis of 5,6-thionocarbonates,
sulfates and sulfites.186, 187 A cyclic 3,5,6-orthoester was shown to have reacted likewise
by basic solvolysis.188 Ishido et al. described the photochemical cyclization of a
![Page 71: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/71.jpg)
70
substituted oxolane ring (Fig. 3.18).189 Yamaguchi et al. showed that the mercaptolysis
of agar as a convenient method for the synthesis of 3,6-anhydro-L-galactose diethyl
dithioacetal.190
Fig. 3.18 Solvolysis
Very little research has been done on the preparation of anhydro-D-glycal sugars, which
are of great importance in the synthesis of complex new derivatives. 3,6-Anhydro-D-
glucal was earlier synthesized by Tucker et al. from 3,4-di-O-acetyl-6-O-tosyl-D-glucal
using Deacidite FF IP (OH-) resin in 66% yield (Fig. 3.19).191 4,6-O-anhydro-D-glucal
was previously reported as a byproduct (40% yield) when an equimolar amount of
lithium aluminum hydride in THF was reacted with 6-O-tosyl-D-glucal, though the
structure of this molecule was not fully characterized.192
Fig. 3.19 Synthesis of 3,6-anhydro-D-glucal
![Page 72: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/72.jpg)
71
The results presented describe the synthesis of 3,6-anhydro-D-glucal from 6-O-tosyl-D-
glucal using excess LiAlH4 in THF as the reagent. With this combination of reagents, an
82% yield of anhydro-D-glycal was realized.193 The unusual chemical reactivity of the
resulting anhydro glycal was also investigated. Also described is the synthesis of an
unusual 1,4:3,6-dianhydrosugar via N-iodosuccinimide (NIS) addition to the 3,6-
anhydro-D-glucal.
3.3 Results: Synthesis of 3,6-anhydro-D-glucal and a study of its chemical
reactivity
3,4,6-Tri-O-acetyl-D-glucal was deacetylated using Zemplen conditions to give D-glucal
16 in 98% yield.194 The resulting D-glucal 16 was selectively tosylated at the primary
hydroxyl using p-toluenesulfonyl chloride in a mixture of pyridine and dichloromethane.
The 6-O-tosylated-D-glucal 17 was obtained in 56% isolated yield. Treatment of 17 with
three equivalents of LiAlH4 in THF did not produce the anticipated 6-deoxy-D-glycal, as
previously reported, but instead gave the 3,6-anhydro sugar 18 in 82% yield (Scheme
3.1).195
Scheme 3.1 Synthesis of 3,6-anhydro-D-glucal
Structural assignments for 18 were based on 1D and 2D 1H and 13C-NMR experiments.
The proposed bridged structure was supported by the observation of long range
![Page 73: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/73.jpg)
72
coupling between the vinylic proton at C2 and the bridgehead proton at C4 (W-coupling)
in the proton NMR. In the 1H-1H-COSY (Appendix), coupling between H4 and H6 and
H6’ was also seen, while in the 1H-NMR the H6 and H6’ peaks only appeared as broad
doublets of doublets. X-ray quality crystals were obtained and the structure of the
molecule established unambiguously (Fig. 3.18), detailed information of which is given
in the Appendix.196
Fig. 3.18 ORTEP representation of compound 18
Compound 18 was subjected to a series of different glycal addition reactions. Treatment
of compound 18 with NIS in the presence of methanol led to the formation of a mixture
of β-gluco-, -manno- and -manno-2-deoxy-2-iodo-O-methylglycosides (19a, 19b, 19c)
in a ratio of 5.2: 1.5: 1 with an overall yield of 93% (Scheme 3.2).197 None of the -gluco
diastereomer was detected in the mixture.
![Page 74: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/74.jpg)
73
Scheme 3.2 Synthesis of 2-deoxy-2-iodo-O-methylglycosides
Treatment of 18 with thiophenol in the presence of a catalytic amount of ceric (IV)
ammonium nitrate (CAN) gave a mixture of α- and β-2-deoxy sugars (20a, 20b) in a
ratio 1.85:1 with a 65% yield. Also formed in the reaction was an α-, β-mixture of the
Ferrier rearranged adducts (21a, 21b) with a 35% yield in a ratio of 2.5:1, formed upon
the breakdown of the anhydride ring (Scheme 3.3).198
Scheme 3.3 Addition of thiophenol to 18 in the presence and absence of CAN
![Page 75: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/75.jpg)
74
When the anhydro sugar 18 was reacted with thiophenol and a catalytic amount of ceric
(IV) ammonium nitrate in the presence of sodium iodide, a reagent known to enhance -
selectivity, a mixture of α- and β-2-deoxy sugars (20a, 20b) was again obtained in this
reaction (34%), but only the α-adduct 21a from the Ferrier rearrangement was isolated
(65%) (Scheme 3.3).199
Because of the success of the NIS addition with methanol, attempts were made to
synthesize disaccharides from the anhydro sugar donor. Compound 18 was treated with
an equimolar amount of 1,2:3,4-di-O-isopropylidine-D-galactopyranose (DIPG) in the
presence of N-iodosuccinimide to give 2-deoxy-2-iodo-1,4:3,6-dianhydride 22 as the
major product (48%). An inseparable mixture of 2-deoxy-2-iodo sugars (23a, 23b, 23c)
was also formed in low yield, and residual starting materials were isolated (~20%)
(Scheme 3.4). When the same reaction was repeated in the absence of 1,2:3,4-di-O-
isopropylidine-D-galactopyranose and in the presence of 4 Ǻ molecular sieves, 22 was
obtained in a much higher yield of 76% (Scheme 3.5).
Scheme 3.4 Synthesis of 1,4:3,6-dianhydride 22 from 18 in the presence of DIPG
![Page 76: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/76.jpg)
75
Scheme 3.5 Synthesis of 1,4:3,6-dianhydride 22 from 18 in the absence of DIPG
3.4 Summary
In summary, good yields of 3,6-anhydro-D-glucal 18 have been obtained from 6-O-
tosyl-D-glucal 17 via reaction with excess lithium aluminum hydride. The resulting
anhydro glycal was studied under a variety of reaction conditions. Iodoglycosylation of
18 with methanol gave good yields of a mixture of 2-deoxy-2-iodomethylglycosides 19a-
c, but attempts to use the primary hydroxyl sugar donor 1,2:3,4-diisopropylidine-D-
galactopyranose gave the dianhydro sugar 22 and iodohydrins 23a-c. These observed
products may result due to the steric hindrance present in the anhydro glycal reactant or
in the transition state for the reaction. Alternatively, unfavorable dipole-dipole
interactions in the transition state for the sugar nucleophile approaching the glycal
double bond may be responsible for the observed products. β-Anomers were favored
over α-anomers by a ratio of ~ 4:1. Furthermore, the formation of 22 is favored because
the intramolecular attack by the bridgehead hydroxyl group is anticipated to be faster
entropically than is the attack by the solvated nucleophiles. The small methanol
nucleophile and adventitious water can more easily access the double bond and
mixtures of product resulted from their attack. In those cases where the DIPG was
excluded and freshly powdered and activated 4 Ao molecular sieves were added, only
the dianhydro sugar 22 was obtained. Further reactions with 18 are ongoing.
![Page 77: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/77.jpg)
76
4.1 Experimental
General Methods.
Melting points (mp) were recorded on a Mel-Temp melting point apparatus (Laboratory Devices,
Inc., USA) and are uncorrected. Proton nuclear magnetic resonance (1H NMR) spectra were
recorded on a Varian Inova (500 MHz) spectrometer. NMR samples were dissolved in CDCl3,
and chemical shifts were reported in ppm relative to the residual non-deuterated solvent (CHCl3
as δ = 7.26 ppm). 1H NMR data are reported as follows: chemical shift, integration, multiplicity
(s = singlet; d = doublet; d, d = doublet of a doublet; d, d, d = doublet of a doublet of a doublet;
m = multiplet), coupling constant, and assignment. 13C NMR spectra were recorded on a Varian
Inova (125 MHz) spectrometer. The samples were dissolved in CDCl3, and chemical shifts are
reported in ppm relative to the solvent (CDCl3 as δ = 77.0 ppm). 1H and 13C NMR spectra were
measured at room temperature and the chemical shifts are reported in parts per million, unless
otherwise noted. 1H NMR assignments were done using gCOSY and 13C NMR assignments were
done using gHMQC. Elemental analysis was performed at Robertson Microlit Laboratories Inc.,
Ledgewood, NJ. High resolution and low resolution mass spectra (HRMS and LRMS) were
obtained at the Mass Spectrometry Lab, University of Illinois, Champaign-Urbana, IL and are
reported in m/z (electrospray ionization). X-ray crystallographic data for compound 2 was
deposited at the Cambridge Crystallographic Data Center (CCDC); deposition number CCDC
988697.20 Reactions were monitored by thin-layer chromatography (TLC) on 0.25 mm silica gel
coated aluminum sheet 60 F254 (Analtech, # 157017). Silica gel (particle size 40-63 µm, 230-400
mesh Silicycle Siliflash P60) was used for flash column chromatography. Preparative thin-layer
chromatographic separations were carried out on 2000 µm silica gel coated glass plate 60 F254
(Analtech). Rotary evaporation was performed using a Buchi R-114 rotary evaporator. Unless
![Page 78: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/78.jpg)
77
otherwise noted, non-aqueous reactions were carried out in oven-dried (125 oC) glassware under
nitrogen. Dry CH3CN, THF and methanol were purchased from Pharmco-Aaper products, Inc.
All other commercially available reagents were used as received.
Thiophenyl-2,3,4,6-tetra-O-acetyl-β-D-galactopyranose (2): To a solution of penta-O-acetyl-
β-D-galactopyranose (9 g, 23.056 mmol) in 30 mL of anhydrous CHCl3 in a 100 mL r. b. f. was
added 2.84 mL of thiophenol (3.048 g, 1.2 eq, 27.667 mmol) under an atmosphere of N2. To the
mixture was then added 7.3 mL of BF3. Et2O and stirred at room temperature for 3 days. The
reaction was then terminated by diluting with excess CHCl3, followed by washings with
saturated NaHCO3 soln. (2 x 50 mL) and 10% w/v NaOH soln. (2 x 50 mL). The organic extract
was dried over anhydrous Na2SO4 and concentrated in vacuo to yield the crude product. The
product was purified by flash column chromatography using 30%, 40% and 50% EtOAc in
hexanes to give 9.809 g (97%) of the desired compound as a white solid. Rf (1:1 EtOAc/
hexanes): 0.66; 1H NMR (500 MHz, CDCl3) δ 7.49-7.51 (m, 2H, Ar), 7.26-7.31 (m, 3H, Ar),
5.41 (dd, 1H, J3,4 = 3.4 Hz, J4,5 = 1 Hz, H-4), 5.23 (dd, 1H, J1,2 = 10 Hz, J2,3 = 9.8 Hz, H-2), 5.04
(dd, J2,3 = 10.2 Hz, J3,4 = 3.4 Hz, H-3), 4.71 (d, 1H, J1,2 = 10.3, H-1), 4.18 (dd, 1H, J6,6’ = 11.45,
J5,6’ = 6.8, H-6’), 4.1 (dd, 1H, J5,6 = 5.8, J6,6’ = 12.1, H-6), 3.93-3.95 (m, 1H, H-5); 13C NMR (125
MHz, CDCl3) δ 170.36, 170.19, 170.04, 169.42 (C=O, OAc), 132.57, 132.47, 128.89, 128.16
(CH, Ar), 86.6 (C-1), 74.42 (C-5), 72 (C-2), 67.26, 67.22 (C-3, C-4), 61.63 (C-6), 20.85, 20.66,
20.63, 20.58 (CH, OAc).
Thiophenyl-β-D-galactopyranose (3): To a solution of the above obtained thiophenyl adduct
(8.33 g, 18.93 mmol) in 30 mL of anhydrous CH3OH was added 0.1 eq of 5% NaOCH3 in
CH3OH solution. The mixture was stirred at room temperature for 4 h under an atmosphere of
N2. The reaction upon reaching completion was rotary evaporated to get rid of CH3OH. The
![Page 79: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/79.jpg)
78
resulting syrupy product was then dried under high vacuum to give 5.1589 g (100%) of the
desired deacetylated product as a yellowish-white powder. Rf (5% CH3OH/CHCl3): 0.03; 1H
NMR (500 MHz, CDCl3) δ 7.43-7.45 (d, 2H, JAr,Ar = 6.3 Hz, Ar), 7.27-7.31 (m, 2H, Ar), 7.18-
7.21 (m, 2H, Ar), 4.72 (s, 4H, -OH), 4.57 (d, 1H, J1,2 = 9.8 Hz, H-1), 3.71 (d, 1H, J3,4 = 3.4 Hz,
H-3), 3.46-3.53 (m, 3H, H-5, 6, 6’), 3.42 (d, 1H, J1,2 = 9.3 Hz, H-2), 3.35 (dd, 1H, J3,4 = 3.4 Hz,
J4,5 = 9 Hz, H-4); 13C NMR (125 MHz, CDCl3) δ 140.76, 134.49, 134, 131.3 (CH, Ar), 92.95 (C-
1), 84.37 (C-5), 79.9 (C-2), 74.46 (C-6), 73.54 (C-3), 65.77 (C-4).
Thiophenyl-4,6-O-benzylidene-β-D-galactopyranose (4): Into an oven-dried 250 mL r. b. f.
was taken ZnCl2 (14.27 g, 5 eq) and flame fused under an atmosphere of N2 to make it totally
anhydrous. To the cooled r. b. f. containing fused ZnCl2 was added benzaldehyde (12.21 g, 5.5
eq) and thiophenyl-β-D-galactopyranose (5.69 g, 20.945 mmol) and the mixture was stirred
under an atmosphere of N2 overnight. Additionally, 15 mL of benzaldehyde was added to the
mixture, for it being the only solvent used in this reaction. When the reaction was found to have
almost reached completion, it was diluted with excess CHCl3 and washed with saturated
NaHCO3 solution (2 x 50 mL). The organic layer was separated and dried over anhydrous
Na2SO4, and evaporated in vacuo to get a crude viscous oily mass. The crude product was
purified by flash column chromatography using gradient dilution technique (40%, 50%, 60%,
70%, 80% and 90% EtOAc in hexanes) to result in 5.2 g (70%) of the desired benzylidene
adduct as a solid white powder. Rf (80% EtOAc/hexanes): 0.245; 1H NMR (500 MHz, CDCl3) δ
8.12-8.14 (m, 2H, Ar), 7.69-7.71 (m, 2H, Ar), 7.61-7.65 (m, 1H, Ar), 7.48-7.51 (m, 1H, Ar),
7.41-7.43 (m, 2H, Ar), 7.37-7.4 (m, 2H, Ar), 5.53 (s, 1H, Bn-Ar), 4.53 (dd, 1H, J1,2 = 4.4 Hz, J1,3
= 2.2 Hz, H-1), 4.4 (dd, 1H, J6,6’ = 12.7 Hz, J5,6’ = 1.5 Hz, H-6), 4.23 (d, 1H, J3,4 = 1.5 Hz, H-4),
4.04 (dd, 1H, J6,6’ = 12.45 Hz, J5,6’ = 2 Hz, H-6’), 3.71-3.75 (m, 2H, H-2, 5), 3.55 (d, 1H, J3,4 = 1
![Page 80: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/80.jpg)
79
Hz); 13C NMR (125 MHz, CDCl3) δ 137.6, 133.7, 133.69, 130.18, 129.34, 128.93, 128.48,
128.23, 128.18, 126.54 (CH, Ar), 101.4 (Bn-Ar), 87 (C-1), 75.4 (C-4), 73.8 (C-5), 70.06 (C-3),
69.28 (C-6), 68.8 (C-2).
Thiophenyl-3-O-benzoyl-4,6-O-benzylidene-β-D-galactopyranose (5a): 4.834 g (13.4 eq) of
thiophenyl-4,6-O-benzylidene-β-D-galactopyranose was taken into an oven-dried 250 mL screw-
cap tube and to it was added 60 mL of anhydrous toluene. The sealed tube was heated to 117 oC
upon thorough stirring for three days in the presence of 4 Ao molecular sieves. After three days,
the tube was cooled to r.t., filtered and evaporated in vacuo to yield a syrupy liquid. To the
syrupy liquid was added 15 mL of anhydrous CHCl3 and an ice-cooled solution of benzoyl
chloride (1.977 g, 1.05 eq) in 15 mL of anhydrous CHCl3. The mixture was stirred for 2 h at r. t.
after which it was evaporated in vacuo to yield 7.838 g of the crude product as a yellowish-
orange solid. Gradient dilution technique (30%, 40%, 50% and 60% EtOAc in hexanes) was
used to purify the crude by flash column chromatography to yield 1.928 g (31%) of the desired
product as an oily colourless liquid. 0.71 g of a mixture of the 2-O-benzyl- and the 3-O-benzyl-
adducts was also obtained. Rf (30% EtOAc/hexanes): 0.327 (Rf of the 2-O-benzyl adduct: 0.39);
1H NMR (500 MHz, CDCl3) δ 8.03-8.05 (m. 2H, Ar), 7.72-7.7 (m, 2H, Ar), 7.53-7.56 (m, 1H,
Ar), 7.38-7.42 (m, 5H, Ar), 7.31-7.38 (m, 4H, Ar), 7.25-7.28 (m, 1H, Ar), 5.51 (s, 1H, Bn-Ar),
5.19 (dd, 1H, J2,3 = 11.3 Hz, J3,4 = 3.1 Hz, H-3), 4.68 (d, 1H, J1,2 = 9.5 Hz, H-1), 4.51 (s, 1H, H-
4), 4.42 (d, 1H, J6,6’ = 12.3 Hz, H-6), 4.06-4.18 (m, 2H, H-2, 6’), 3.7 (s, 1H, H-5); 13C NMR (125
MHz, CDCl3) δ 165.9 (-CO-Ar), 137.3, 133, 130, 129.9, 128, 127.8, 126.3 (CH, Ar), 108.9 (Bn-
Ar), 93.1 (C-1), 79.3 (C-4), 79.2 (C-5), 74.4 (C-3), 71.2 (C-2), 67.8 (C-6); LRMS (ESI): Calcd
C26H24O6S: 464.1. Found for (M+Na)+: 487.1.
![Page 81: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/81.jpg)
80
Thiophenyl-2-O-acetyl-3-O-benzoyl-4,6-O-benzylidene-β-D-galactopyranose (6): To a
solution of the above obtained thiophenyl-3-O-benzoyl-4,6-O-benzylidene-β-D-galactopyranose
(2 g, 4.31 mmol) in 10 mL of N, N, N-triethylamine was added N, N-dimethylaminopyridine
(38.67 mg, 0.08 eq) and stirred at 0 oC for 30 min. To the ice-cold solution was added 507.54 mg
(1.5 eq) of acetyl chloride drop-wise and the reaction was vigorously stirred at 0 oC initially and
at r.t. for 2 days. The reaction was terminated by diluting with CH2Cl2 (50 mL) and, by washing
with 2 N HCl (2 x 25 mL) and saturated NaHCO3 solution (2 x 25 mL). The organic layer was
dried over anhydrous MgSO4 and evaporate in vacuo to give 2.44 g of the crude product as an
orange fluffy solid. Purification was carried out by flash column chromatography using 30%
EtOAc in hexanes as the eluent. 1.3 g (60%) of the desired product was obtained as a yellow oily
liquid. Rf (30% EtOAc/hexanes): 0.44; 1H NMR (500 MHz, CDCl3) δ 7.99-7.97 (m, 2H, Ar),
7.63-7.64 (m, 2H, Ar), 7.52-7.55 (m, 1H, Ar), 7.31-7.41 (m, 8H, Ar), 5,56 (d, 1H, J2,3 = 9.9 Hz,
H-2), 5.48 (s, 1H, Bn-Ar), 5.2 (dd, 1H, J1,2 = 9.9 Hz, J2,3 = 9.8 Hz, H-3), 4.79 (d, 1H, J1,2 = 9.8
Hz, H-1), 4.54 (s, 1H, H-4), 4.42 (d, 1H, J6,6’ = 12.4 Hz, H-6), 4.06 (d, 1H, J6,6’ = 12.4 Hz, H-6’),
3.69 (s, 1H, H-5), 2.01 (s, 3H, -CO-CH3); 13C NMR (125 MHz, CDCl3) δ 170.1 (-CO-CH3),
165.9 (-CO-Ar), 137.3, 133.9, 133, 130, 129.3, 128.6, 127.8, 125 (CH, Ar), 108.9 (Bn-Ar), 89.8
(C-1), 79.6 (C-4), 78.9 (C-5), 73.8 (C-3), 70.4 (C-2), 67.8 (C-6), 21.0 (CH3); LRMS (ESI): Calcd
C28H26O7S: 506.1. Found for (M+NH4)+: 524.2.
Thiophenyl-2-O-acetyl-3-O-benzoyl-β-D-galactopyranose (7a): To a solution of thiophenyl-2-
O-acetyl-3-O-benzoyl-4,6-O-benzylidene-β-D-galactopyranose in anhydrous dichloromethane
(20 mL) at -15 oC was added drop-wise a mixture of 20% v/v trifluoroacetic acid (880 mg, 6 eq)
in CH2Cl2. The mixture was brought to r.t. and stirred overnight in an atmosphere of N2. The
reaction was terminated by the addition of excess CH2Cl2 (30 mL), and washed with saturated
![Page 82: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/82.jpg)
81
NaHCO3 solution (2 x 25 mL) and water (2 x 25 mL). The organic layer was separated and dried
over anhydrous Na2SO4, and evaporated in vacuo to yield 820 mg of the crude 4,6-diol sugar.
The compound was purified by flash column chromatography by gradient dilution method (30%,
40%, 50% and 60% EtOAc in hexanes) to yield 244 mg (45%) of the pure product. Rf (30%
EtOAc/hexanes): 0.137; 1H NMR (500 MHz, CDCl3) δ 7.98-8.0 (m, 3H, Ar), 7.93-7.95 (m, 2H,
Ar), 7.52-7.58 (m, 3H, Ar), 7.44-7.45 (m, 2H, Ar), 5.58 (d, 1H, J1,2 = 9.9 Hz, H-2), 5.22 (dd, 1H,
J2,3 = 9.9 Hz, J3,4 = 3.1 Hz, H-3), 5.07 (d, 1H, J1,2 = 10.1 Hz, H-1), 4.42 (d, 1H, J3,4 = 3.1 Hz, H-
4), 4.06 (m, 1H, H-5), 3.84 (m, 2H, H-6, 6’), 1.97 (s, 3H, -CO-CH3); 13C NMR (125 MHz,
CDCl3) δ 170.1 (-CO-CH3), 165.9 (-CO-Ar),133.9, 133, 129.3, 129.3, 129.9, 128, 125.1 (CH,
Ar), 89.8 (C-1), 86.3 (C-5), 73.3 (C-3), 70.1 (C-2), 67.7 (C-4), 61.2 (C-6), 21.0 (CH3); HRMS
(ESI): Calcd C21H23O7S for (M+H)+: 419.1165. Found: 419.1173.
Thiophenyl-2-O-acetyl-3-O-benzoyl-4,6-O-pyruvate-β-D-galactopyranose (7): To a
suspension of thiophenyl-2-O-acetyl-3-O-benzoyl-β-D-galactopyranose (10 mg, 0.024 mmol) in
methyl pyruvate (57.5 mg, 23.5 eq) was added BF3-Etherate drop-wise. The mixture was allowed
to stir at r.t. overnight in an atmosphere of N2. The reaction was terminated by the addition of 1
mL of N, N, N-triethylamine to neutralize the acid. The mixture was poured into 25 mL of
saturate NaHCO3 solution and extracted with CH2Cl2 (2 x 50 mL). The organic layer was dried
over anhydrous Na2SO4 and evaporated in vivo to give the desired pyruvate adduct in its crude
form. The crude product was purified by preparatory TLC using 50% EtOAc in hexanes mixture
as the eluent (with trace amounts of N, N, N-triethylamine) to give 10 mg (80%) of the pyruvate
adduct. Rf (50% EtOAc/hexanes): 0.77; 1H NMR (500 MHz, CDCl3) δ 7.97-8.01 (m, 3H, Ar),
7.92-7.95 (m, 2H, Ar), 7.5-7.54 (m, 2H, Ar), 7.44-7.49 (m, 3H, Ar), 5.45-5.47 (m, 1H, H-2),
5.29-5.34 (m, 1H, H-3), 5.08 (dd, 1H, J1,2 = 10 Hz, J1,3 = 2.8 Hz, H-1), 4.63 (dd, 1H, J3,4 = 7.8 Hz,
![Page 83: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/83.jpg)
82
J4,5 = 3.4, H-4), 4.09-4.1 (m, 1H, H-6), 4.06-4.07 (m, 1H, H-6’), 3.89-3.9 (m, 1H, H-5), 3.27 (s,
3H, -OCH3), 2.01 (s, 3H, -CO-CH3), 1.63 (s, 3H, CH3); 13C NMR (125 MHz, CDCl3) δ 170.2 (-
CO-CH3), 168.9 (-CO-OCH3), 165.9 (-CO-Ar) 133.9, 133, 130.1, 129.3, 128.6, 125.1 (Ar),
114.9 (Pyr), 89.8 (C-1), 79.1 (C-4), 78.9 (C-5), 73.8 (C-3), 70.4 (C-2), 65.1 (C-6), 52.5 (-CO-
OCH3), 25.5 (CH3), 21.0 (-CO-CH3); HRMS (ESI): Calcd C25H26O9NaS for (M+Na)+: 525.1195.
Found: 525.1205.
4-O-tert-butyldimethylsilyl-cyclohexanol (12a): To a solution of cis/trans mixture of 1, 4-
cyclohexanediol (200 mg, 1.72 mmol) in N, N-dimethylformamide (5 mL) was added 2.5 eq of
imidazole (292. 7 mg) and the mixture was stirred at r.t. 30 min. To the solution was added tert-
butyldimethylsilyl chloride (1.25 eq, 292.7 mg) and the mixture was stirred for 3 days in an
atmosphere of N2. At the end of the third day, the mixture was diluted with excess CH2Cl2 (30
mL), washed with water (5 x 25 mL) and saturated NaCl (aq) solution (1 x 25 mL). The organic
layer was dried over anhydrous Na2SO4 and then evaporated in vacuo to give 276 mg of the
crude product. Purification was done by flash column chromatography using 50% EtOAc in
hexanes as the eluent which gave 196 mg (50%) of the product. Rf (50% EtOAc/hexanes): 0.87;
1H NMR (500 MHz, CDCl3) δ 3.79-3.83 (m, 1H, H-1), 3.65-3.70 (m, 1H, H-4), 1.6-1.77 (m, 6H,
H-2a, 2e, 3e, 5e, 6a, 6e), 1.46-1.5 (m, 1H, H-3a), 1.28-1.32 (m, 1H, H-5a), 0.89 (s, 9H, t-butyl),
0.04 (s, 6H, CH3); 13C NMR (125 MHz, CDCl3) δ 78.1 (C-4), 69.7 (C-1), 32.1 (C-2, 6), 31.3 (C-
3, 5), 30.9 (-CCH3, t-butyl), 25.9 (-CCH3, t-butyl), -2.0 (CH3).
2-Phthalimido-per-O-acetyl-β-D-glucopyranose (9): To a solution of NaOCH3 (2 g, 37.037
mmol) in CH3OH (60 mL) in an oven dried 250 mL r. b. f. was added glucosamine HCl (10 g,
46.3 mmol) and the mixture was stirred at r. t. in an atmosphere of N2 for 30 min. 6.852 g of
phthalic anhydride (1 eq) was added to the mixture and was stirred at r. t. for 20 h. The reaction
![Page 84: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/84.jpg)
83
was terminated by evaporating the solvent in vacuo. To the solid residue obtained was added 60
mL of acetic anhydride and 50 mL of pyridine and the mixture was stirred at r. t. for 42 h for per-
acetylating the sugar. The reaction was terminated by adding 100 g of ice and stirring the
mixture for 30 min. The mixture was extracted with CH2Cl2 (2 x 150 mL). The combined
organic extracts were washed with 3M H2SO4 solution (4 x 100 mL), water (2 x 150 mL),
saturated NaHCO3 and water (2 x 150 mL) again sequentially. The organic layer was dried over
anhydrous Na2SO4, filtered and concentrated to dryness in vacuo to give 18.42 g of a yellow
fluffy solid. Flash column chromatography of the crude product by gradient dilution method
(40%, 50% and 60% EtOAc/hexanes) gave 6.54 g (30%) of the desired pure product. Rf (40%
EtOAc/hexanes): 0.32; 1H NMR (500 MHz, CDCl3) δ 7.85-7.87 (m, 2H, Ar), 7.73-7.76 (m, 2H,
Ar), 6.51 (d, 1H, J1,2 = 8.9 Hz, H-1), 5.88 (dd, 1H, J2,3 = 10.6 Hz, J3,4 = 9.1 Hz, H-3), 5.21 (d, 1H,
J3,4 = 10 Hz, H-4), 4.46 (dd, 1H, J2,3 = 10.6 Hz, J1,2 = 8.9 Hz, H-2), 4.36 (dd, 1H, J6,6’ = 12.4 Hz,
J5,6 = 4.4 Hz, H-6), 4.11-4.14 (m, 1H, H-6’), 4.01-4.04 (m, 1H, H-5), 2.11 (s, 3H, -CO-CH3),
2.04 (s, 3H, -CO-CH3), 2.00 (s, 3H, -CO-CH3), 1.86 (s, 3H, -CO-CH3); 13C NMR (125 MHz,
CDCl3) δ 172.9, 170.2 (-CO-CH3), 167.6 (-CO-N-), 132.2, 123.7 (Ar), 93.4 (C-1), 74.7 (C-5),
70.8 (C-3), 69.9 (C-4), 61.9 (C-2), 62.4 (C-6), 21.0 (-CO-CH3).
Thioethyl-2-phthalimido-3,4,6-tri-O-acetyl-β-D-glucopyranose (10): To a solution of 2-
phthalimido-per-O-acetyl-β-D-glucopyranose (1.5 g, 3.14 mmol) in 30 mL of CHCl3 in a clean
oven dried 100 mL r. b. f. was added ethanethiol (1.2 eq, 234 mg) and the mixture was stirred at
r. t. for 15 min in an atmosphere of N2. To the mixture was added BF3. Et2O drop-wise and the
mixture was stirred at r. t. for 4 days. When TLC showed that the reaction reached completion,
the mixture was diluted with 100 mL of CH2Cl2, washed with saturated NaHCO3 solution (2 x
150 mL) and 10% w/v NaOH (aq) solution (1 x 100 mL). The combined organic layers were
![Page 85: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/85.jpg)
84
dried over anhydrous Na2SO4 and concentrated to dryness in vacuo to give 1.35 g of a red fluffy
solid. The crude product was purified by flash column chromatography, using 50% EtOAc in
hexanes as the eluent, to yield 1.188 g (79%) of the pure product. Rf (50% EtOAc/hexanes):
0.49; 1H NMR (500 MHz, CDCl3) δ 7.85-7.86 (m, 2H, Ar), 7.73-7.76 (m, 2H, Ar), 5.82 (dd, 1H,
J2,3 = 10.3 Hz, J3,4 = 9.2 Hz, H-3), 5.48 (d, 1H, J1,2 = 10.7 Hz, H-1), 5.17 (dd, 1H, J4,5 = 10.1 Hz,
J3,4 = 9.2 Hz, H-4), 4.39 (d, 1H, J1,2 = 10.4 Hz, H-2), 4.3 (dd, 1H, J6,6’ = 12.4 Hz, J5,6 = 4.9 Hz, H-
6), 4.17 (dd, 1H, J6,6’ = 12.3 Hz, J5,6’ = 2.3 Hz, H-6’), 3.89 (ddd, 1H, J4,5 = 10.25 Hz, J5,6 = 4.85
Hz, J5,6’ = 2.4 Hz, H-5), 2.62-2.71 (m, 2H, -S-CH2-CH3), 2.10 (s, 3H, -CO-CH3), 2.03 (s, 3H, -
CO-CH3), 1.86 (s, 3H, -CO-CH3), 1.21 (t, 3H, JCH2,CH3 = 7.3 Hz, -S-CH2-CH3); 13C NMR (125
MHz, CDCl3) δ 170.2 (-CO-CH3), 169.6 (-CO-N-), 132.2, 123.8 (Ar), 81.3 (C-1), 76.12 (C-5),
71.7 (C-3), 69.1 (C-4), 62.48 (C-6), 53.86 (C-2), 24.52 (-S-CH2-CH3), 20.91, 20.77, 20.6 (-CO-
CH3), 15.04 (-S-CH2-CH3).
(4-tert-butyldimethylsilyl-cyclohexyl)-2-phthalimido-3,4,6-tri-O-acetyl-β-D-glucopyranose
(13): Into a clean oven dried 25 mL r. b. f. was taken 575 mg (1.2 mmol) of thioethyl-2-
phthalimido-3,4,6-tri-O-acetyl-β-D-glucopyranose, To it was added 15 mL anhydrous CH2Cl2
and the mixture was cooled to -78 oC (acetone/dry ice) upon stirring in an inert atmosphere. To
the mixture was added N-iodosuccinimide (2.5 eq, 675 mg) and stirred at -78 oC for 30 min.
Keeping the temperature constant, 10 µL (0.05 eq) of trimethylsilyl trifluoromethanesulfonate
(TMSOTf) was added drop-wise to the mixture upon vigorous stirring. To the mixture was added
drop-wise a solution of 4-O-tert-butyldimethylsilyl-cyclohexanol (1.2 eq, 331.2 mg) in CH2Cl2
(2 mL) and the reaction was stirred at -78 oC for 90 min. The reaction was terminated and the
mixture was diluted with excess CH2Cl2 (100 mL) and washed with saturated NaHCO3 solution
(1 x 50 mL). The organic layer was dried over anhydrous MgSO4, filtered and concentrated to
![Page 86: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/86.jpg)
85
dryness in vacuo to yield a gram of the crude product as a dark brown oily syrup. Purification
was done by flash column chromatography using gradient dilution (30%, 40%, 50%, 60%, 70%,
80%, 90% EtOAc in hexanes) which yielded 503 mg (65%) of the product as a pale yellow oily
syrup. Rf (60% EtOAc/hexanes): 0.83; 1H NMR (500 MHz, CDCl3) δ 7.84-7.87 (m, 2H, Ar),
7.71-7.75 (m, 2H, Ar), 5.76-5.83 (m, 1H, H-3), 5.44 (dd, 1H, J1,2 = 8.75 Hz, J1,3 = 2.4 Hz, H-1),
5.13-5.18 (m, 1H, H-4), 4.28-4.35 (m, 2H, H-2, 6), 4.16 (d, 1H, J6,6’ = 12.2 Hz, H-6’) 3.84-3.87
(m, 1H, H-5), 3.59-3.68 (m, 1H, Cyclohexyl-H-1), 3.49-3.53 (m, 1H, Cyclohexyl-H-4), 2.11 (s,
3H, -CO-CH3), 2.03 (s, 3H, -CO-CH3), 1.86 (s, 3H, -CO-CH3), 1.68-1.8 (m, 2H, Cyclohexyl-H-
2e, 6e), 1.24-1.40 (m, 4H, Cyclohexyl-H-3e, 2a, 5e, 6a), 1.19-1.40 (m, 1H, Cyclohexyl-H-3a), 0.83
(s, 5H, H-t-butyl), 0.74 (s, 4H, H-t-butyl), -0.04 (s, 3H, CH3), -0.08 (s, 3H, CH3), -0.12 (s, 3H,
CH3); 13C NMR (125 MHz, CDCl3) δ 172.96, 171.06 (-CO-CH3), 169.84 (-CO-N-), 134.57,
123.92 (Ar), 97.05 (C-1), 72.11 (C-5), 71.21 (C-3), 69.59 (C-4), 62.60 (C-6), 49.66 (C-2), 31.13
(-CCH3, t-butyl), 26.15, 26.02 (-CCH3, t-butyl), 21.13, 21, 20.82 (-CO-CH3), -4.43 (CH3);
LRMS (ESI): Calcd C32H45NO11Si: 647.3. Found for (M+H)+: 648.3.
Cyclohexyl-2-phthalimido-3,4,6-tri-O-acetyl-β-D-glucopyranose (14): Into a clean oven dried
10 mL r. b. f. was taken 25 mg (0.052 mmol) of thioethyl-2-phthalimido-3,4,6-tri-O-acetyl-β-D-
glucopyranose, To it was added 5 mL anhydrous CH2Cl2 and the mixture was cooled to -78 oC
upon stirring in an inert atmosphere. To the mixture was added N-iodosuccinimide (2.5 eq, 29.34
mg) and stirred at -78 oC (acetone/dry ice) for 30 min. Keeping the temperature constant, 0.46
µL (0.05 eq) of trimethylsilyl trifluoromethanesulfonate (TMSOTf) was added drop-wise to the
mixture upon vigorous stirring. To the mixture was added drop-wise a solution of 4-O-tert-
butyldimethylsilyl-cyclohexanol (1.2 eq, 14.35 mg) in CH2Cl2 (1 mL) and the reaction was
stirred at -78 oC for 7 h. The reaction was terminated and the mixture was diluted with CH2Cl2
![Page 87: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/87.jpg)
86
(25 mL) and washed with saturated NaHCO3 solution (1 x 25 mL). The organic layer was dried
over anhydrous MgSO4, filtered and concentrated to dryness in vacuo to yield the crude product
as a orange-brown oily syrup. Purification was done by preparatory TLC technique using 80%
EtOAc in hexanes as the solvent which yielded 32 mg (95%) of the product as a yellowish oily
syrup. Rf (60% EtOAc/hexanes): 0.157; 1H NMR (500 MHz, CDCl3) δ 7.84-7.86 (m, 2H, Ar),
7.72-7.76 (m, 2H, Ar), 5.75-5.82 (m, 1H, H-3), 5.44 (dd, 1H, J1,2 = 8.4 Hz, J1,3 = 6.4 Hz, H-1),
5.15-5.19 (m, 1H, H-4), 4.28-4.36 (m, 2H, H-2, 6), 4.16 (m, 1H, J6,6’ = 10.8 Hz, H-6’), 3.85-3.88
(m, 1H, H-5), 3.73-3.77 (m, 1H, Cyclohexyl-H-1), 3.56-3.65 (m, 1H, Cyclohexyl-H-4), 2.11 (s,
3H, -CO-CH3), 2.03 (s, 3H, -CO-CH3), 1.95-1.98 (m, 1H, Cyclohexyl-H-2e), 1.86 (s, 3H, -CO-
CH3), 1.69-1.76 (m, 1H, Cyclohexyl-H-6e), 1.33-1.43 (m, 2H, Cyclohexyl-H-3e, 5e), 1.17-1.31
(m, 2H, Cyclohexyl-H-3a, 5a); 13C NMR (125 MHz, CDCl3) δ 170.73, 170.22 (-CO-CH3),
169.51, 165.52 (-CO-N-), 134.35, 131.38, 123.6 (Ar), 96.85 (C-1), 76.86 (Cyclohexyl-C-1),
71.78 (C-3, 5), 70.88 (C-4), 69.19 (Cyclohexyl-C-4), 62.23 (C-6), 54.86 (C-2), 30.47, 30.06
(Cyclohexyl-C-2, 3, 5, 6), 20.78, 20.65, 20.46 (-CO-CH3). LRMS (ESI): Calcd C26H31NO11:
533.2. Found for (M+H)+: 534.2.
(Cyclohexyl-2-phthalimido-3,4,6-tri-O-acetyl-β-D-glucopyranosyl)-2-O-acetyl-3-O-benzoyl-
4,6-O-pyruvate-β-D-galactopyranose (15): 61.279 mg (1.3 eq) of thiophenyl-2-O-acetyl-3-O-
benzoyl-4,6-O-pyruvate-β-D-galactopyranose and 5 mL of anhydrous CH2Cl2 were taken in a
clean oven tried 10 mL r. b. f. and the mixture was stirred at -42 oC (CH3CN/dry ice) in an inert
atmosphere for 15 min. 68.625 mg (2.5 eq) of N-iodosuccinimide was added to the mixture and
stirred for 30 min at -42 oC. Keeping the temperature constant, 1.3 µL of TMSOTf (0.05 eq) was
added to the mixture drop-wise upon vigorous stirring. To the mixture was added a solution of
cyclohexyl-2-phthalimido-3,4,6-tri-O-acetyl-β-D-glucopyranose (50 mg, 0.0939 mmol) in
![Page 88: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/88.jpg)
87
anhydrous CH2Cl2 (1 mL) and the reaction was run at -42 oC for 3 h upon continuous stirring.
The reaction was terminated by adding excess CH2Cl2 (40 mL), washed with saturated NaHCO3
solution (1 x 50 mL) and 10% w/v Na2S2O3 solution (1 x 50 mL). The organic layer was
separated, dried over anhydrous MgSO4, filtered and concentrated to dryness in vacuo to yield
135 mg of the crude product as an orange oily syrup. Purification was done by preparatory TLC
technique using 60 % EtOAc in hexanes as the solvent, which gave 50 mg (57.6%) of the
product as an off white coloured solid. 1H NMR (500 MHz, CDCl3) δ 7.99-8.04 (m, 2H, Ar),
7.91-7.96 (m, 1H, Ar), 7.83-7.88 (m, 1H, Ar), 7.73-7.77 (m, 1H, Ar), 7.49-7.54 (m, 1H, Ar),
7.36-7.41 (m, 1H, Ar), 7.35-7.41 (m, 2H, Ar), 5.73-5.80 (m, 1H, Hglu-1), 5.62-5.66 (m, 1H,
Hgal-1), 5.36-5.46 (m, 2H, Hglu-3, Hgal-2), 5.13-5.19 (m, 1H, Hgal-3), 4.48-4.60 (m, 1H, Hglu-4),
4.26-4.34 (m, 2H, Hgal-4, Hglu-2), 4.10-4.27 (m, 2H, Hglu-5, 6), 3.93-4.08 (m, 2H, Hglu-6’, Hgal-6),
3.80-3.90 (m, 2H, Hgal-6’, Cyclohexyl-H-1), 3.73-3.78 (m, 1H, Hgal-5), 3.61-3.7 (m, 3H, -OCH3),
3.41-3.53 (m, 1H, Cyclohexyl-H-4), 2.11 (s, 1H, -CO-CH3), 2.10 (s, 1H, -CO-CH3), 2.06 (s, 1H,
-CO-CH3), 1.87 (s, 1H, -CO-CH3), 1.86 (s, 1H, -CO-CH3), 1.85 (s, 1H, -CO-CH3), 1.65-1.83 (m,
4H, Cyclohexyl-H-2a, 2e, 6a, 6e), 1.57 (s, 3H, -CO-CH3), 1.37-1.42 (m, 1H, Cyclohexyl-H-
3e),1.27-1.31 (m, 1H, Cyclohexyl-H-5e) 1.25 (s, 3H, CH3), 0.86-0.92 (m, 1H, Cyclohexyl-H-3a);
13C NMR (125 MHz, CDCl3) δ 170.70, 170.20 (-CO-CH3), 169.49 (-CO-OCH3), 165.89 (-CO-
N-), 134.37, 133.16, 131.31, 129.88, 129.77, 129.67, 128.42, 128.36, 127.47, 123.61 (Ar),
100.36 (pyr), 98.69 (Cgal-1), 96.65 (Cglu-1), 96.12 (Cyclohexyl-C-1), 95.91 (Cyclohexyl-C-4),
72.04 (Cgal-4), 71.93 (Cgal-5), 71.79 (Cglu-5), 70.82 (Cgal-3), 69.22 (Cglu-3), 69.13 (Cgal-4), 66.7
(Cgal-2), 65.34 (Cgal-6), 64.01 (Cglu-6), 62.17 (Cglu-2), 54.8 (CO-OCH3), 31.93, 29.70, 29.36,
28.98 (Cyclohexyl-C-2, 3, 5, 6), 25.72 (CH3), 20.78, 20.65, 20.47 (-CO-CH3); HRMS (ESI):
Calcd C45H51NO20Na for (M+Na)+: 948.2902. Found: 948.2899.
![Page 89: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/89.jpg)
88
4.2. 6-O-p-toluenesulfonyl-D-arabino-hex-1-enitol (17).
To a solution of D-glucal (7.6 g, 52.5 mmol) in anhydrous pyridine was added dropwise a
solution of p-toluenesulfonyl chloride (15.02 g, 78.8 mmol) in anhydrous CH2Cl2 at 0 oC upon
vigorous stirring. The reaction was terminated after 3 h by the addition of water, followed by
washing with saturated CuSO4 (3 x 30 mL), water (5 x 30 mL) and brine (1 x 30 mL). The
organic extracts were dried under anhydrous MgSO4 and concentrated in vacuo to yield crude
17. Although the compound was synthesized earlier,13 no spectroscopic data was reported. The
product was purified by flash chromatography using 3%, 4% and 5% CH3OH in CHCl3 mixtures
to give 8.18 g (56% yield) of 17 as a colorless oily mass which crystallized upon freezing: Rf
(1:20 CH3OH/CHCl3): 0.46; mp 50–51 oC; 1H NMR (500 MHz, CDCl3) δ 7.81 (d, 2H, J = 6.3
Hz, Ar), 7.35 (d, 2H, J = 7.9 Hz, Ar), 6.24 (d, 1H, J1,2 = 6.1, J1,3 = 1.8 Hz, H-1), 4.74 (dd, 1H, J2,1
= 6.3, J2,3 = 2.2 Hz, H-2), 4.47 (dd, 1H, J6,6’ = 11.25, J6,5 = 4Hz, H-6), 4.28 (dd, 1H, J6,6’ = 11.45,
J6’,5 = 2.5 Hz, H-6’), 4.26 (d, 1H, J3,4 = 6.8 Hz, H-3), 3.91 (ddd, 1H, J5,4 = 9.75, J5,6 = 3.9, J5,6’ = 2
Hz, H-5), 3.76 (dd, 1H, J4,3 = 8.3, J4,5 =8.3 Hz, H-4), 3.09 (s, 1H, 4-OH), 2.45 (s, 3H, PhCH3),
2.23 (s, 1H, 3-OH); 13C NMR (125 MHz, CDCl3) δ 145.19 (CH, Ar), 143.99 (C-1), 132.61,
129.93 , 128.02 (CH, Ar), 103.04 (C-2), 75.7 (C-5), 69.57 (C-3), 69.35 (C-4), 67.92 (C-6), 21.66
(PhCH3).
4.3. 3,6-Anhydro-2-deoxy-D-arabino-hex-1-enitol (18).
To a solution of 17 (200 mg, 0.33 mmol) in 20 mL of tetrahydrofuran (THF) was added
dropwise 0.83 mL of 2.4 M LiAlH4 in THF (2 mmol) at 0 oC. The mixture was refluxed at 73 oC
for two days. It was then cooled to 0 oC and neutralized with 15% w/v NaOH and water, and
filtered through a Celite@ bed upon dilution with ethyl acetate (EtOAc). The mixture was
concentrated in vacuo and the product was purified by flash chromatography using 1:1 mixture
![Page 90: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/90.jpg)
89
of EtOAc/Hexanes to give 73 mg (84%) of 18 as a white solid: Rf (1:20 CH3OH/CHCl3): 0.42;
D]22 -24.17 (c 0.58, CHCl3); 1H NMR (500 MHz, CDCl3) δ 6.54 (d, 1H, J1,2 = 5.0 Hz, H-1),
5.02 (ddd, 1H, J2,1 = 5.25, J2,3 = 5.5, J2,4 = 1.5 Hz, H-2), 4.36 (br dd, 1H, J5,6 =3.65, J5,6’ =3.65
Hz, H-5), 4.27 (d, 1H, J6’,6 =11.2 Hz, H-6’), 4.23-4.2 (m, 1H, H-4), 4.18 (dd, 1H, J6,6’ = 11.3, J5,6
= 4.5 Hz, H-6), 4.03 (br dd, 1H, J3,4 =4.5, J3,2= 5.5 Hz, H-3), 2.09 (d, 1H, J4,-OH = 10.7 Hz, 4-OH);
13C NMR (125 MHz, CDCl3) δ 146.53 (C-1), 100.41 (C-2), 76.56 (C-5), 74.71 (C-6), 68.76 (C-
3), 66.26 (C-4); Anal. Calcd. for C6H8O3: C, 56.24; H, 6.29. Found: C, 56.15; H, 6.42.
4.4 . General procedure for the synthesis of 3,6-anhydro-O-glycosides.
To a solution of 50 mg (0.39 mmol) of 18 in 5 mL of anhydrous CH3CN at 0 oC was added
105.5 mg (0.47mmol) of N-iodosuccinimide. To the solution was then added 1.2 equivalents of
the desired nucleophile and the reaction mixture was stirred at r. t. overnight. The solvent was
evaporated in vacuo and the crude product was purified by preparatory thin-layer
chromatography (TLC) using 1:50 CH3OH/CHCl3 as the solvent.
4.4.1. Methyl-3,6-anhydro-2-deoxy-2-iodo-gluco- and manno-pyranosides (19a, 19b, 19c).
Data for the mixture of diastereomers: 1H NMR (500 MHz, CDCl3) δ 5.31 (s, 1H), 5.03 (d,
1H, J = 7.8 Hz), 4.72 (s, 1H), 4.47 (dd, 1H, J = 4.4 Hz, J = 3.4 Hz), 4.42-4.44 (m, 1H), 4.39-4.36
(m, 2H), 4.28-4.32 (m, 2H), 4.24 (d, 2H, J = 10.7 Hz), 4.15-4.12 (m, 1H), 4.09-4.06 (m, 3H),
3.96 (dd, 1H, J = 10 Hz, J = 5 Hz), 3.91 (dd, 1H, J = 5 Hz, J = 10 Hz), 3.54 (s, 1H), 3.48 (s, 1H),
3.46 (s, 1H), 2.64 (d, 1H, J = 8.8 Hz), 2.44 (d, 1H, J = 5 Hz), 2.41 (d, 1H, J = 8.8 Hz), 2.04 (d,
1H, J = 5.3 Hz); 13C NMR (125 MHz, CDCl3) δ 80.43, 72.81, 69.06, 29.57, 26.60, 20.28; HRMS
(ESI): Calcd C7H11O4NaI for (M+Na)+: 308.9611. Found: 308.9600.
4.5. General procedure for the synthesis of 2-deoxythioglycosides.
![Page 91: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/91.jpg)
90
To a stirred solution of 50 mg (0.39 mmol) of 18 and 21 mg (0.039 mmol) of Ce(NH4)2(NO3)6
in anhydrous CH3CN (5 mL) was added a solution of 0.2 mL (1.95 mmol) of PhSH in anhydrous
CH3CN (5 mL) at 0 oC and allowed to stir overnight at r.t.. The solvent was evaporated in vacuo
and the residue was diluted with excess CH2Cl2, washed with 10% NaOH, saturated NaHCO3
and saturated NaCl and, dried over anhydrous Na2SO4. The organic solvent was evaporated in
vacuo and the crude (150 mg) obtained was purified by preparatory TLC using 1:50
CH3OH/CHCl3 as the solvent to give mixtures of compounds 20a, 20b (60 mg) and 21a, 21b (33
mg).
4.5.1. Thiophenyl-3,6-anhydro-2-deoxy-D-glucopyranoside (20a, 20b).
Data for α-anomer (20b): Rf (1:50 CH3OH/CHCl3): 0.84; 1H NMR (500 MHz, CDCl3) δ 7.54-
7.50 (m, 2H, Ar), 7.33-7.24 (m, 3H, Ar), 5.73 (dd, 1H, J1,2 = 8.0, J1,2’ = 3.2 Hz, H-1), 4.69-4.67
(m, 1H, H-5), 4.59 (dd, 1H, J2,3 = 5.4, J3,4 = 1.2 Hz, H-3), 4.29-4.26 (m, 1H, H-4), 3.99 (dd, 1H,
J6,6’ = 9.7, J5,6 = 4.4 Hz, H-6), 3.84 (dd, 1H, J6,6’ = 9, J5,6’ = 5.5 Hz, H-6’), 3.06 (d, 1H, J4,-OH =
10.7 Hz, 4-OH), 2.63 (ddd, 1H, J2,2’ = 14.15, J1,2 = 8.55, J2,3 = 6.3 Hz, H-2), 2.35 (ddd, 1H, J2,2’ =
14.1, J1,2’ = 3.15, J2’,3 = 1.3 Hz, H-2’); 13C NMR (125 MHz, CDCl3) δ 132.3, 130.8, 129.1 (CH,
Ar), 89.8 (C-1), 85.17 (C-5), 82.9 (C-3), 74.86 (C-6), 71.83 (C-4), 40.6 (C-2); HRMS (ESI):
Calcd C12H14O3NaS for (M+Na)+: 261.0570. Found: 261.0561. Data for β-anomer (20a): Rf
(1:50 CH3OH/CHCl3): 0.76; 1H NMR (500 MHz, CDCl3) δ 7.54-7.50 (m, 2H, Ar), 7.33-7.24 (m,
3H, Ar), 5.66 (dd, 1H, J1,2 = 6.8, J1,2’ = 1.3 Hz, H-1), 4.69-4.67 (m, 1H, H-5), 4.64 (dd, 1H, J3,4 =
5.4, J2,3 = 1.2 Hz, H-3), 4.26-4.25 (m, 1H, H-4), 3.82 (dd, 1H, J6,6’ = 9.55, J5,6’ = 5.7 Hz, H-6’),
3.63 (dd, 1H, J6,6’ = 9.5, J5,6 = 6.2 Hz, H-6), 2.58 (d, 1H, J4,-OH = 7.4 Hz, 4-OH), 2.5 (ddd, 1H,
J2,2’ = 14.1, J1,2 = 6.35, J2,3 = 2 Hz, H-2), 2.17-2.22 (m, 1H, H-2’); 13C NMR (125 MHz, CDCl3) δ
![Page 92: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/92.jpg)
91
129, 127.78, 127.35 (CH, Ar), 88.41 (C-1), 82.52 (C-5), 82.39 (C-3), 73.16 (C-6), 72.12 (C-4),
40.77 (C-2); HRMS (ESI): Calcd C12H14O3NaS for (M+Na)+: 261.0570. Found: 261.0561.
4.5.2. Thiophenyl-2,3-dideoxy-D-glucopyranoside (21a, 21b).
Data for α-anomer (21a): Rf (1:50 CH3OH/CHCl3): 0.19; 1H NMR (500 MHz, CDCl3) δ
7.51-7.53 (m, 2H, Ar), 7.26-7.33 (m, 3H, Ar), 6.0 (dd, 1H, J1,2 = 10.2 Hz, J2,3 = 2 Hz, H-2), 5.98
(d, 1H, J1,2 = 10.2 Hz, H-1), 5.74 (dd, 1H, J3,4 = 1.2 Hz, J2,3 = 2.7 Hz, H-3), 4.32 (dd, 1H, J3,4 = 2
Hz, J4,5 = 8.75 Hz, H-4), 4.03-4.07 (m, 1H, H-5), 3.86-3.92 (m, 2H, H-6, 6’), 1.85 (d, 1H, J4,-OH =
7.3 Hz, 4-OH), 1.82 (dd, 1H, J6,-OH = 6.35 Hz, J6’,-OH = 6.4 Hz, 6-OH); 13C NMR (125 MHz,
CDCl3) δ 131.77, 129.03, 127.32 (CH, Ar), 131.72 (C-1), 127.12 (C-2), 83.61 (C-3), 71.88 (C-5),
64.29 (C-4), 62.91 (C-6); HRMS (ESI): Calcd C12H14O3NaS for (M+Na)+: 261.0561. Found:
261.0561. Data for β-anomer (21b): Rf (1:50 CH3OH/CHCl3): 0.19; 1H NMR (500 MHz,
CDCl3) δ 7.51-7.53 (m, 2H, Ar), 7.26-7.33 (m, 3H, Ar), 5.88 (dd, 1H, J1,2 = 2 Hz, J2,3 = 1.9 Hz,
H-2), 5.86 (dd, 1H, J1,2 = 1.5 Hz, J2,3 = 1.4 Hz, H-1), 4.72-4.78 (m, 1H, H-4), 4.54-4.60 (m, 1H,
H-5), 4.11-4.16 (m, 2H, H-6, 6’), 2.18-2.24 (m, 4-OH, 6-OH); 13C NMR (125 MHz, CDCl3) δ
135.10, 132.5, 131.69 (CH, Ar), 131.62 (C-1), 128.84 (C-2), 81.74 (C-3), 79.74 (C-5), 63.40 (C-
4), 62.75 (C-6); HRMS (ESI): Calcd C12H14O3NaS for (M+Na)+: 261.0561. Found: 261.0561.
4.6. General procedure for the preparation of the dianhydrosugar.
To 100 mg (0.78 mmol) of 18 in 10 mL of CH3CN was added 210 mg (0.94 mmol) of N-
iodosuccinimide in the presence of 4 Ǻ molecular sieves, and allowed to stir overnight at r.t. The
solvent was removed in vacuo and the residue was diluted with excess CH2Cl2, washed with 10%
Na2S2O3, saturated NaCl and dried over anhydrous Na2SO4. The organic filtrate was evaporated
in vacuo and the crude product (170 mg) was purified by flash chromatography using 2:3
![Page 93: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/93.jpg)
92
EtOAc/Hexanes to give 150 mg (0.61 mmol, 76 %) of 22. In the absence of activated sieves, a
mixture of 2-deoxy-2-iodo-hexopyranoses (23a-c), were also obtained (30%).
4.6.1. 1,4:3,6-Dianhydro-2-deoxy-2-iodo-D-glucopyranose (22).
Data for the dianhydrosugar: Rf (1:50 CH3OH/CHCl3): 0.9; 1H NMR (500 MHz, CDCl3) δ
5.51 (br s, 1H, H-1), 5.09 (dd, 1H, J4,3= 4.25, J4,5 = 4.5 Hz, H-4), 4.27 (dd, 1H, J5,4 = 3.5, J5,6 =
3.25 Hz, H-5), 4.18 (dd, 1H, J3,2 = 7.0, J3,4 = 5.0 Hz, H-3), 4.15 (d, 1H, J6,6’ = 10.8 Hz, H-6’), 4.0
(dd, 1H, J2,3 = 7.0, J2,1 = 2.0 Hz, H-2), 3.94 (dd, 1H, J6,6’ =10.7, J5,6 = 3.0 Hz, H-6); 13C NMR
(125 MHz, CDCl3) δ 100.20 (C-1), 79.87 (C-4), 77.02 (C-5), 73.28 (C-3), 71.30 (C-6), 32.85 (C-
2); LRMS (ESI) m/Z (rel. intensity) 254.9 (M+H)+ (79).
4.6.2. 3,6-anhydro-2-deoxy-2-iodo-D-hexopyranose (23a, 23b, 23c).
Data for mixture of diastereomers: Rf 1:50 CH3OH/CHCl3): 0.12; 1H NMR (500 MHz,
CDCl3) δ 5.76 (s, 1H), 5.68 (d, 1H, J = 5 Hz), 5.38 (s, 1H), 5.02 (dd, 1H, J = 5.4 Hz, J = 4.9 Hz),
4.89 (d, 1H, J =), 4.83 (ddd, 1H, J = 15 Hz, J = 5 Hz, J = 5 Hz), 4.73-4.70 (m, 2H), 4.48 (d, 1H, J
= 1.4 Hz), 4.44 (d, 1H, J = 4.9 Hz), 4.40-4.37 (m, 2H), 4.19 (dd, 1H, J = 4.9 Hz, J = 4.4 Hz), 4.14
(dd, 1H, J =), 4.09-4.06 (m, 2H), 4.04-3.98 (m, 2H), 3.79-3.76 (m, 2H), 3.62 (dd, 1H, J = 9.5 Hz,
J = 6.6 Hz); 13C NMR (125 MHz, CDCl3) δ 107.69, 99.48, 96.06, 90.68, 84.04, 83.32, 82.26,
76.37, 75.55, 71.75, 70.55, 46.57, 46.56, 26.66, 25.12, 23.61, 8.72, 8.71; LRMS (ESI): Calcd
C6H9IO4: 271.9. Found for (M+Na)+: 294.8.
![Page 94: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/94.jpg)
93
4.2 NMR Spectra
![Page 95: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/95.jpg)
94
vb_276_pure_1H.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
No
rma
lize
d In
ten
sity
7.5
17
.51
7.5
0
7.3
2
7.3
17
.30 7.3
07
.26
5.4
15
.41
5.4
1 5.2
35
.21
5.0
55
.05
4.7
24
.70
4.1
94
.18
4.1
6 4.1
14
.10
4.1
04
.09
3.9
5 3.9
3
2.1
32
.11
2.0
92
.03
1.9
61
.96
![Page 96: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/96.jpg)
95
vb_276_pure_13C.esp
200 180 160 140 120 100 80 60 40 20
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
No
rma
lize
d In
ten
sity
170
.35
170
.18
170
.03
169
.41
132
.56
128
.89
128
.16
86.6
0
77.3
17
7.0
67
6.8
07
4.4
27
2.0
06
7.2
2
61.6
3
20.8
52
0.6
32
0.5
8
![Page 97: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/97.jpg)
96
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
F2 Chemical Shif t (ppm)
2
4
6
F1 C
he
mic
al S
hift (
pp
m)
![Page 98: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/98.jpg)
97
8 7 6 5 4 3 2 1 0
F2 Chemical Shif t (ppm)
0
20
40
60
80
100
120
F1 C
he
mic
al S
hift (pp
m)
![Page 99: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/99.jpg)
98
vb_277_pure_1H.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
No
rma
lize
d In
ten
sity 7.4
67
.45
7.4
47
.29
7.2
87
.20
7.1
8
4.7
24
.58
4.5
7
3.7
23
.71
3.5
43
.53
3.5
23
.49
3.4
73
.43
3.4
13
.36
3.3
6
3.3
43
.34
2.5
12
.50
2.5
02
.50
2.4
9
![Page 100: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/100.jpg)
99
vb_277_pure_13C.esp
150 140 130 120 110 100 90 80 70 60 50 40 30 20 10
Chemical Shift (ppm)
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
No
rma
lize
d In
ten
sity
135
.51
129
.21
128
.74
126
.03
87.6
8
79.1
0
74.5
8
69.1
46
8.2
0
60.4
4
![Page 101: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/101.jpg)
100
8 7 6 5 4 3 2 1 0
F2 Chemical Shif t (ppm)
0
2
4
6
8
F1 C
he
mic
al S
hift (pp
m)
![Page 102: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/102.jpg)
101
9 8 7 6 5 4 3 2 1 0
F2 Chemical Shif t (ppm)
20
40
60
80
100
120 F1 C
he
mic
al S
hift (p
pm
)
![Page 103: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/103.jpg)
102
vb_285_B_1H.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
No
rma
lize
d In
ten
sity
8.1
4 8.1
4 8.1
28
.12
7.7
2 7.7
07
.70
7.6
37
.50
7.3
97
.39
7.3
27
.30
7.2
9
5.5
3
4.5
44
.52
4.4
14
.41 4.3
94
.23
4.2
34
.06
4.0
5
3.7
53
.74
3.7
3
3.7
23
.71
3.5
63
.55
![Page 104: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/104.jpg)
103
vb_285_B_13C.esp
170 160 150 140 130 120 110 100 90 80 70 60 50 40 30
Chemical Shift (ppm)
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
No
rma
lize
d In
ten
sity
137
.62
133
.71
130
.18
128
.47
128
.23
126
.53
101
.39
87.0
0
77.2
97
7.0
47
6.7
97
5.3
97
3.8
27
0.0
66
9.2
86
8.8
0
![Page 105: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/105.jpg)
104
9 8 7 6 5 4 3 2 1
F2 Chemical Shif t (ppm)
2
4
6
8 F1 C
he
mic
al S
hift (p
pm
)
![Page 106: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/106.jpg)
105
9 8 7 6 5 4 3 2
F2 Chemical Shif t (ppm)
40
60
80
100
120
140
F1 C
hem
ica
l S
hift (p
pm
)
![Page 107: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/107.jpg)
106
vb_153_B.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
No
rma
lize
d In
ten
sity
8.0
5 8.0
3
7.7
27
.70
7.5
47
.42
7.4
17
.27
7.2
67
.25
7.2
5
5.5
15
.21
5.2
05
.19
5.1
84
.69
4.6
74
.51
4.5
14
.41
4.1
54
.13
4.1
24
.12
4.0
84
.06
3.7
0
1.8
1
1.2
81
.27 1
.26
1.2
50
.96
0.9
50
.94
![Page 108: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/108.jpg)
107
8 7 6 5 4 3 2 1
F2 Chemical Shif t (ppm)
2
4
6
8
F1
C
hem
ica
l S
hift (p
pm
)
![Page 109: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/109.jpg)
108
vb_162_A.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
No
rma
lize
d In
ten
sity
7.9
97
.97
7.6
3
7.5
27
.41
7.3
97
.37
7.3
57
.26
5.5
85
.56
5.4
8
5.2
15
.19
4.8
04
.78
4.5
44
.43
4.4
0
4.0
74
.05
3.6
9
2.0
1
![Page 110: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/110.jpg)
109
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
F2 Chemical Shif t (ppm)
2
4
6
F1
C
hem
ica
l S
hift (p
pm
)
![Page 111: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/111.jpg)
110
vb_169_B
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
No
rma
lize
d In
ten
sity
4.001.231.731.851.811.37
M04(d)
M03(d)M07(m)
M06(m)
M01(t)
M02(dd)
8.0
08
.00
7.9
87
.98
7.9
57
.93
7.6
67
.64 7
.47
7.4
57
.44
7.4
2 7.4
2
5.6
0 5.5
85
.56
5.2
3
5.0
85
.06
4.4
24
.42
4.0
74
.05
4.0
43
.84
3.8
43
.83
1.9
71
.97
1.9
6
![Page 112: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/112.jpg)
111
8 7 6 5 4 3 2
F2 Chemical Shif t (ppm)
2
4
6
8
F1 C
he
mic
al S
hift (pp
m)
![Page 113: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/113.jpg)
112
vb_171_pure
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
No
rma
lize
d In
ten
sity
7.9
97
.99
7.9
87
.98
7.9
47
.93
7.5
27
.52
7.5
07
.47
7.4
5
5.4
75
.47
5.4
55
.32
5.3
15
.30
5.1
05
.09
5.0
85
.07
4.6
34
.09
4.0
74
.07
4.0
73
.90
3.2
73
.27
3.2
63
.25
2.0
01
.99
1.6
31
.63
1.6
21
.62
1.5
9
![Page 114: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/114.jpg)
113
8 7 6 5 4 3 2 1
F2 Chemical Shif t (ppm)
2
4
6
8
F1 C
he
mic
al S
hift (pp
m)
![Page 115: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/115.jpg)
114
vb_259_pure_1H.esp
9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
No
rma
lize
d In
ten
sity
7.8
7
7.8
6 7.8
67
.76
7.7
57
.75
7.7
4
7.7
47
.73
7.2
6
6.5
26
.50
5.9
15
.89
5.8
85
.87
5.2
35
.21
4.4
94
.47
4.4
74
.37
4.3
64
.35
4.1
64
.14
4.1
34
.11
4.0
1
2.1
22
.11 2.0
42
.00
1.8
6
![Page 116: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/116.jpg)
115
8 7 6 5 4 3 2
F2 Chemical Shif t (ppm)
2
4
6
8
F1 C
he
mic
al S
hift (pp
m)
![Page 117: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/117.jpg)
116
vb_266_pure_1H.esp
9 8 7 6 5 4 3 2 1
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
No
rma
lize
d In
ten
sity
7.8
6 7.7
57
.75
7.7
47
.74
7.2
6
5.8
5 5.8
35
.81
5.5
05
.48
5.2
0 5.1
85
.16
4.4
24
.40
4.3
24
.30
4.2
94
.19
4.1
93
.91
3.9
03
.89
2.7
2 2.7
12
.69
2.6
72
.65
2.1
32
.11
2.1
12
.03
1.8
6
1.2
61
.23
1.2
21
.20
![Page 118: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/118.jpg)
117
vb_266_pure_13C.esp
180 160 140 120 100 80 60 40 20 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
No
rma
lize
d In
ten
sity
170
.70
169
.47
123
.72
81.2
27
7.2
67
7.0
17
6.7
67
5.9
77
1.5
96
8.9
5
62.3
3
53.7
1
24.3
72
0.7
72
0.6
32
0.4
51
4.9
0
![Page 119: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/119.jpg)
118
8 7 6 5 4 3 2 1
F2 Chemical Shif t (ppm)
2
4
6
8
F1 C
he
mic
al S
hift (pp
m)
![Page 120: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/120.jpg)
119
8 7 6 5 4 3 2 1
F2 Chemical Shif t (ppm)
50
100
F1 C
he
mic
al S
hift (pp
m)
![Page 121: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/121.jpg)
120
vb_238_A_1H
5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
No
rma
lize
d In
ten
sity
TMS
3.8
13
.67
3.6
7
1.7
3 1.7
11
.70
1.6
61
.65
1.5
01
.48
1.4
61
.30
1.3
0
0.8
9
0.0
4
![Page 122: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/122.jpg)
121
vb_268_pure_1H
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
No
rma
lize
d In
ten
sity
7.8
67
.85
7.8
57
.84
7.7
57
.26
7.2
57
.25
5.7
85
.78
5.7
65
.45
5.4
45
.43
5.4
35
.17
5.1
75
.15
4.3
44
.33
4.3
24
.31
4.3
14
.30
4.1
73
.87
3.8
63
.66
3.6
3
2.1
12
.03
1.8
6
1.5
41
.52
1.2
61
.25
1.2
5
0.8
80
.83
0.7
40
.73
0.0
5-0
.03
-0.0
4
![Page 123: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/123.jpg)
122
vb_268_pure_13C
180 160 140 120 100 80 60 40 20 0
Chemical Shift (ppm)
-0.01
0
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
No
rma
lize
d In
ten
sity
172
.96 1
69
.84
134
.57
123
.92
97.0
5
77.6
17
7.3
57
7.1
07
2.1
17
1.2
16
9.5
96
2.6
0
49.6
6
26.1
52
6.0
72
1.1
32
1.0
02
0.8
2
-4.4
3
![Page 124: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/124.jpg)
123
8 7 6 5 4 3 2 1 0
F2 Chemical Shif t (ppm)
0
2
4
6
8
F1
Ch
em
ica
l S
hift
(p
pm
)
![Page 125: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/125.jpg)
124
8 7 6 5 4 3 2 1 0
F2 Chemical Shif t (ppm)
0
50
100
F1
Ch
em
ica
l S
hift
(p
pm
)
![Page 126: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/126.jpg)
125
vb_269_B_1H
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
No
rma
lize
d In
ten
sity
7.8
77
.86
7.8
6
7.8
57
.75
7.7
57
.75
7.2
77
.27
7.2
67
.26
7.2
6
5.8
15
.80
5.7
95
.78
5.4
65
.45
5.4
55
.44
5.4
35
.17
5.1
64
.34
4.3
44
.32
4.3
24
.30
4.1
84
.17
4.1
53
.87
3.8
53
.75
3.6
0
2.1
22
.11
2.0
31
.95
1.8
71
.87
1.8
6
1.8
61
.74
1.7
21
.39
1.3
81
.37
1.2
61
.25
![Page 127: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/127.jpg)
126
vb_269_B_13C
180 160 140 120 100 80 60 40 20 0
Chemical Shift (ppm)
0
0.005
0.010
0.015
0.020
0.025
0.030
No
rma
lize
d In
ten
sity
170
.24
169
.51
134
.37
131
.36
123
.62
98.6
69
6.8
49
6.4
6
77.2
67
7.0
17
6.7
67
1.7
77
0.8
36
9.2
26
8.8
76
2.2
0
54.8
1
30.4
5
28.7
82
7.0
72
0.7
92
0.6
62
0.4
7
![Page 128: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/128.jpg)
127
8 7 6 5 4 3 2 1
F2 Chemical Shif t (ppm)
2
4
6
8
F1
C
hem
ica
l S
hift (p
pm
)
![Page 129: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/129.jpg)
128
8 7 6 5 4 3 2 1
F2 Chemical Shif t (ppm)
20
40
60
80
100
120
F1
Ch
em
ica
l S
hift
(p
pm
)
![Page 130: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/130.jpg)
129
vb_272_A_1H.esp
8 7 6 5 4 3 2 1
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
No
rma
lize
d In
ten
sity
8.0
48
.02
8.0
07
.85 7
.75
7.7
57
.74
7.5
27
.38
7.2
6
5.7
75
.75
5.6
4
5.4
15
.39
5.1
65
.15
5.1
34
.32
4.3
14
.31
4.3
04
.28
4.0
63
.85
3.8
43
.68 3
.67
3.6
43
.62
3.4
8
2.1
22
.11
2.1
12
.03
1.8
51
.75
1.6
1
1.5
71
.54
1.4
11
.25
1.2
31
.21
0.8
70
.86
0.0
6
![Page 131: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/131.jpg)
130
vb_272_pure_13C
180 160 140 120 100 80 60 40 20
Chemical Shift (ppm)
0
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
No
rma
lize
d In
ten
sity
170
.70
170
.20
169
.49
165
.89
163
.34
147
.56
134
.37
133
.16
129
.88
129
.67
128
.42
128
.36
127
.47
123
.61
100
.36
98.6
9 96.6
59
6.1
29
5.9
19
5.3
59
5.0
39
1.3
77
7.2
87
7.0
37
6.7
87
1.9
37
1.7
9 70.8
26
9.2
26
9.1
36
6.7
0
62.1
7
55.8
35
4.8
05
4.7
25
2.4
0
31.9
3
29.7
02
9.3
62
5.7
22
2.6
92
0.7
92
0.6
52
0.4
7
14.1
2
![Page 132: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/132.jpg)
131
8 7 6 5 4 3 2 1
F2 Chemical Shif t (ppm)
2
4
6
8
F1
Ch
em
ica
l S
hift
(p
pm
)
![Page 133: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/133.jpg)
132
vb_196_A_1H
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
No
rma
lize
d In
ten
sity
7.8
27
.81
7.3
7
7.2
6
6.2
56
.24
6.2
3
4.7
54
.75
4.7
44
.73
4.4
74
.46
4.3
04
.30
4.2
84
.27
4.2
63
.91
3.9
03
.90
3.8
93
.76
3.1
03
.10
2.4
5
2.2
3
![Page 134: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/134.jpg)
133
vb_196_A_13C
180 160 140 120 100 80 60 40 20
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
No
rma
lize
d In
ten
sity
145
.18 1
43
.99
132
.60
129
.93
128
.01
103
.03
77.2
67
7.0
07
6.7
57
5.7
06
9.5
76
9.3
56
7.9
2
21.6
6
![Page 135: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/135.jpg)
134
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5
F2 Chemical Shif t (ppm)
3
4
5
6
7
F1 C
he
mic
al S
hift
(pp
m)
![Page 136: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/136.jpg)
135
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0
F2 Chemical Shif t (ppm)
20
40
60
80
100
120
140
F1 C
he
mic
al S
hift (
pp
m)
![Page 137: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/137.jpg)
136
VB_188_A_1H.esp
6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
Chemical Shift (ppm)
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
No
rma
lize
d In
ten
sity
![Page 138: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/138.jpg)
137
vb_188_A_13C
152 144 136 128 120 112 104 96 88 80 72 64
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
No
rma
lize
d In
ten
sity
66.2
6
68.7
6
74.7
17
6.7
67
7.0
27
7.2
7
100
.41
146
.52
![Page 139: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/139.jpg)
138
6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0
F2 Chemical Shif t (ppm)
2
3
4
5
6
F1 C
hem
ica
l S
hift
(p
pm
)
![Page 140: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/140.jpg)
139
6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
F2 Chemical Shif t (ppm)
60
80
100
120
140
F1 C
hem
ica
l S
hift (p
pm
)
![Page 141: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/141.jpg)
140
vb_190_pure_1H
5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
Chemical Shift (ppm)
0
0.05
0.10
0.15
No
rma
lize
d In
ten
sity
5.3
1
5.0
45
.03
4.7
2 4.4
84
.47
4.3
84
.37
4.2
94
.25
4.2
34
.09 4.0
94
.07
4.0
63
.93
3.9
2
3.5
53
.46
2.6
52
.64
2.4
12
.40
2.0
42
.03
1.2
71
.25
![Page 142: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/142.jpg)
141
vb_190_13C
96 88 80 72 64 56 48 40 32 24 16 8
Chemical Shift (ppm)
0
0.05
0.10
No
rma
lize
d In
ten
sity
80.4
37
7.2
57
7.0
07
6.7
5
72.8
1
69.0
6
29.5
7
26.6
0
20.2
8
![Page 143: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/143.jpg)
142
5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
F2 Chemical Shif t (ppm)
1
2
3
4
5
F1 C
hem
ica
l S
hift (p
pm
)
![Page 144: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/144.jpg)
143
5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
F2 Chemical Shif t (ppm)
16
24
32
40
48
56
64
72
80
F1 C
hem
ica
l S
hift (p
pm
)
![Page 145: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/145.jpg)
144
vb_195_B_1H
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0
Chemical Shift (ppm)
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
No
rma
lize
d In
ten
sity
2.0
42
.182.2
2
2.3
42.3
72
.37
2.4
92
.49
2.6
22
.63
2.6
42
.65
2.6
62
.67
3.0
63
.08
3.6
23
.63
3.6
43
.65
3.8
03
.81
3.8
23
.83
3.8
43
.85
3.9
84
.00
4.2
54
.25
4.2
64
.27
4.2
84
.31
4.5
84
.58
4.5
9
4.6
84
.69
4.6
94
.69
5.6
45
.665.7
25
.73
5.7
45
.74
7.2
47
.25
7.2
67
.30
7.3
27
.32
7.3
37
.49
7.5
07
.52
7.5
3
![Page 146: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/146.jpg)
145
vb_195_B_13C
144 136 128 120 112 104 96 88 80 72 64 56 48 40
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
No
rma
lize
d In
ten
sity
40.6
04
0.7
7
71.8
37
3.1
97
4.8
5
82.3
88
2.5
28
2.9
08
5.1
7
88.4
18
9.8
0
127
.35
129
.151
30
.80
132
.32
135
.35
![Page 147: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/147.jpg)
146
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
F2 Chemical Shif t (ppm)
2
3
4
5
6
7
8
F1 C
hem
ica
l S
hift (p
pm
)
![Page 148: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/148.jpg)
147
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
F2 Chemical Shif t (ppm)
40
60
80
100
120
140
F1 C
hem
ica
l S
hift
(p
pm
)
![Page 149: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/149.jpg)
148
vb_199_B_1H
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0
Chemical Shift (ppm)
0
0.05
0.10
No
rma
lize
d In
ten
sity
7.5
37
.53
7.5
17
.51
7.5
17
.34
7.3
37
.32
7.2
6
6.0
16
.00
5.9
9 5.9
8
5.9
55
.95
5.9
3
5.7
55
.74
5.7
4
4.3
3 4.3
24
.06 4
.06
4.0
4
3.9
23
.91
3.8
93
.88
3.8
73
.86
3.8
63
.85
1.8
61
.84
1.8
31
.81
![Page 150: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/150.jpg)
149
vb_199_B_13C
136 128 120 112 104 96 88 80 72 64 56
Chemical Shift (ppm)
0.05
0.10
0.15
No
rma
lize
d In
ten
sity
131
.77
129
.03
127
.56
127
.12
83.6
1
77.2
67
7.0
07
6.7
5
71.8
8
64.2
96
2.9
1
![Page 151: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/151.jpg)
150
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0
F2 Chemical Shif t (ppm)
2
3
4
5
6
7
F1 C
hem
ica
l S
hift (p
pm
)
![Page 152: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/152.jpg)
151
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5
F2 Chemical Shif t (ppm)
64
72
80
88
96
104
112
120
128
136
F1 C
hem
ica
l S
hift (p
pm
)
![Page 153: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/153.jpg)
152
vb_195_C_1H
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
No
rma
lize
d In
ten
sity
7.5
37
.53
7.5
37
.51
7.5
07
.49
7.3
37
.31
7.2
67
.26
7.2
57
.25
7.2
47
.24
6.0
05
.99
5.9
9
5.9
8 5.9
75
.97
5.9
45
.94
5.9
35
.89
5.8
25
.74
5.7
45
.73
5.6
35
.62
5.6
25
.43
5.4
25
.42
5.3
04
.64
4.6
34
.58
4.5
74
.56
4.3
3
4.3
2
4.2
44
.06
4.0
54
.05
4.0
43
.903
.89
3.8
83
.87
3.8
63
.85
3.8
53
.84
3.8
33
.59 3.5
73
.57
3.5
63
.00
2.9
82
.33 2
.31
2.3
0
2.2
32
.22
2.2
02
.19
2.1
82
.04 2
.03
2.0
2
1.7
11
.64
1.3
8 1.3
01
.27
1.2
6
![Page 154: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/154.jpg)
153
vb_195_C_13C
135 130 125 120 115 110 105 100 95 90 85 80 75 70 65 60
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
No
rma
lize
d In
ten
sity
135
.09
132
.48
131
.74
131
.68
131
.52
129
.02
127
.53
127
.00
83.6
5
81.7
4
79.7
37
7.2
77
7.0
17
6.7
6
71.8
7
64.5
66
4.1
8 62.8
26
2.7
4
![Page 155: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/155.jpg)
154
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
F2 Chemical Shif t (ppm)
1
2
3
4
5
6
7
F1 C
hem
ica
l S
hift (p
pm
)
![Page 156: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/156.jpg)
155
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
F2 Chemical Shif t (ppm)
64
72
80
88
96
104
112
120
128
F1 C
hem
ica
l S
hift (p
pm
)
![Page 157: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/157.jpg)
156
vb_197_A_1H
5.5 5.0 4.5 4.0
Chemical Shift (ppm)
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
No
rma
lize
d In
ten
sity
5.5
2
5.1
15
.10
5.0
9 4.2
84
.27
4.2
7
4.2
04
.18
4.1
74
.17
4.1
5
4.0
24
.02
4.0
13
.96
3.9
53
.94
3.9
3
![Page 158: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/158.jpg)
157
vb_197_A_13C
105 100 95 90 85 80 75 70 65 60 55 50 45 40 35 30 25
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
No
rma
lize
d In
ten
sity
32.8
5
71.3
0
73.2
8
76.7
77
7.0
27
7.2
8
79.8
7
100
.20
![Page 159: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/159.jpg)
158
5.5 5.0 4.5 4.0 3.5 3.0
F2 Chemical Shif t (ppm)
3.0
3.5
4.0
4.5
5.0
5.5
F1 C
hem
ica
l S
hift (p
pm
)
![Page 160: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/160.jpg)
159
5.5 5.0 4.5 4.0 3.5 3.0
F2 Chemical Shif t (ppm)
32
40
48
56
64
72
80
88
96
104
F1 C
hem
ica
l S
hift (p
pm
)
![Page 161: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/161.jpg)
160
vb_197_B_1H
5.5 5.0 4.5 4.0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
No
rma
lize
d In
ten
sity
5.7
65
.69
5.6
8
5.4
1
5.0
35
.02
5.0
25
.01
5.0
1
4.8
94
.89
4.8
3
4.7
94
.75
4.7
44
.74
4.7
3
4.4
84
.48
4.4
74
.45 4.4
44
.39
4.3
84
.37
4.3
0
4.2
04
.19
4.1
8
4.1
44
.09
4.0
94
.07
4.0
74
.06
4.0
64
.04
4.0
24
.01
3.7
93
.78
3.7
73
.76
3.7
6
3.6
33
.62
3.6
1
![Page 162: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/162.jpg)
161
vb_197_B_13C
104 96 88 80 72 64 56 48 40 32 24 16 8
Chemical Shift (ppm)
0
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
0.10
0.11
0.12
0.13
No
rma
lize
d In
ten
sity
107
.69
99.4
7
90.6
8
84.0
48
3.3
28
2.2
67
7.2
67
7.0
07
6.7
57
6.3
67
6.2
67
5.5
5
71.7
67
0.5
5
46.5
8
26.6
62
5.1
2
8.7
3
![Page 163: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/163.jpg)
162
5.5 5.0 4.5 4.0 3.5 3.0
F2 Chemical Shif t (ppm)
3.0
3.5
4.0
4.5
5.0
5.5
F1 C
he
mic
al S
hift (
pp
m)
![Page 164: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/164.jpg)
163
5.5 5.0 4.5 4.0 3.5 3.0 2.5
F2 Chemical Shif t (ppm)
30
40
50
60
70
80
90
100
F1 C
he
mic
al S
hift
(pp
m)
![Page 165: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/165.jpg)
164
4.3 REFERENCES
1. Janeway C, Travers P, Walport M, Shlomchik M. Immunobiology, 6th edn.
New York: Garland Science Publishing, 2005.
2. Gourley, T. S.; Wherry, E. J.; Masopust, D.; Ahmed, R. Semin. Immunol. 2004, 16,
323-333.
3. Dakic, A.; Shao, Q. X.; D’Amico, A.; O’Keeffe, M.; Chen, W. F.; Shortman, K.; Wu, L.
J. Immunol. 2004, 172, 1018-1027.
4. Kaufmann, S. H.; Schauble, U. E. Curr. Opin. Immunol. 2005, 17, 79-87.
5. Pamer, E.; Cresswell, P. Annu. Rev. Immunol. 1998, 16, 323-358.
6. Watts, C. Nat. Immunol. 2004, 5, 685-692.
7. Fallon, P. G.; Smith, P.; Dunne, D. W. Eur. J. Immunol. 1998, 28, 1408-1016;
Jardetzky, T. S.; Gorga, J. C.; Busch, R.; Rothbard, J.; Strominger, J. L.; Wiley, D. C.
EMBO J. 1990, 9, 1797-1803.
8. Denzin, L. K.; Cresswell, P. Cell 1995, 82, 155-165.
9. Abbas, A. K.; Lichtman, A. H.; Pober, J. S. Cellular and molecular immunology, 4th
edn., Saunders, 2000
10. de Jong, E. C.; Smits, H. H.; Kapsenberg, M. L. Springer Semin. Immunopathol.
2005, 26, 289-307.
11. Roncarolo, M. G.; Levings, M. K.; Traversari, C. J. Exp. Med. 2001, 193, F5-F9.
12. Velez, C. D.; Lewis, C. J.; Kasper, D. L.; Cobb, B. A. Immunology 2009, 127, 73-82.
13. Cobb, B. A.; Kasper, D. L. Glycobiology 2008, 18, 707-718.
![Page 166: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/166.jpg)
165
14. Moon, J. J.; Chu, H. H.; Pepper, M.; McSorley, S. J.; Jameson, S. C.; Kedl, R. M.;
Jenkins, M. Immunity 2007, 27, 203-213.
15. Cobb, B. A.; Wang, Q.; Tzianabos, A. O.; Kasper, D. L. Cell 2004, 117, 677-87.
16. Kalka-Moll, W. M.; Tzianabos, A. O.; Bryant, P. W.; Niemeyer, M.; Ploegh, H. L.;
Kasper, D. L. J. Immunol. 2002, 169, 6149-6153.
17. Wang, Q.; McLoughin, R. M.; Cobb, B. A.; Charrel-Dennis, M.; Zaleski, K. J.;
Golenbock, D.; Tzianabos, A. O.; Kasper, D. L. J. Exp. Med. 2006, 203, 2853-2863.
18. Tzianabos, A. O.; Onderdonk, A. B.; Rosner, B.; Cisneros, R. L.; Kasper, D. L.
Science 1993, 262, 416-419.
19. Farthmann, E. H.; Schoffel, U. Infection 1998, 26, 329-334.
20. Marshall, J. C.; Innes, M. Crit. Care Med. 2003, 31, 2228-2237.
21. Nichols, R. L. Rev. Infect Dis. 1985, 7, 709-715.
22. Tzianabos, A. O.; Chandraker, A.; kalka-Moll, W.; Stingele, F.; Finberg, R. W.;
Peach, R.; Sayegh, M. H. Infect. Immun. 2000, 68, 6650-6655.
23. Tzianabos, A. O. Clin. Microbiol. Rev. 2000, 13, 523-533.
24. Tzianabos, A. O.; Oncerdonk, A. B.; Smith, r. S.; Kasper, D. L. Infect. Immun. 1994,
62, 3590-3593.
25. Hooper, L. V., Midtvedt, T., Gordon, J. I. Annu. Rev. Nutr. 2002, 22, 283-307.
26. Coyne, M. J., Cornstock, L. E. J. Bacteriol. 2008, 190, 736-742.
27. Wexler, H. M. Clin Microbiol Rev. 2007, 20, 593-621.
28. Xu, J.; Bjursell, M. K.; Himrod, J.; Deng, S.; Carmichael, L. K.; Chiang, H. C.;
Hooper, L. V.; Gordon, J. I. Science 2003, 299, 2074-2076.
![Page 167: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/167.jpg)
166
29. Mazmanian, S. K.; Liu, C. H.; Tzianabos, A. O.; Kasper, D. L. Cell 2005, 122, 107-
118.
30. Gonzalez-Fernandez, A.; Faro, J.; Fernandez, C. Vaccine 2008, 26, 292-300.
31. Janeway, C. A. Garland Science, New York, 2004.
32. Tzianabos, A. O.; Wang, J. Y.; Lee, J. C. Proc. Natl. Acac. Sci. USA 2001, 98, 9365-
9370.
33. Watts, C.; Powis, S. Rev. Immunogenet. 1999, 1, 60-74.
34. Cobb, B. A.; Kasper, D. L. Cell Microbiol. 2005, 7, 1398-1403.
35. Gibson, F. C. 3rd.; Tzianabos, A. O.; Onderdonk, A. B. Infect. Immun. 1996, 64,
1065-1069.
36. Blanco, P.; Palucka, A. K.; Pascual, V.; Banchereau, J. Cytokine Growth Factor
Rev. 2008, 19, 41-52.
37. Cohen-Poradosu, R.; McLoughlin, R. M.; Lee, J. C.; Kasper, D. L. J. Infect. Dis.
2011, 24, 363-371.
38. Ertel, W.; Morrison, M. H.; wang, P.; Ba, Z. F.; Ayala, Z. F.; Ayala, A.; Chaudry, I. H.
Ann. Surg. 1991, 214, 141-148; Smeland, E. B.; Blomhoff, H. K.; Funderud, S.; Shalaby,
M. R.; Espevik, T. J. Exp. Med. 1989, 170, 1463-1468.
39. Gomez, C. R.; Goral, J.; Ramirez, L.; Kopf, M.; Kovacs, E. J. Shock 2006, 25, 581-
585; Helle, M.; Boeije, L.; Aarden, L. A. Eur. J. Immunol. 1988, 18, 1535-1540.
40. Takeda, K.; Kaisho, T.; Yoshida, N.; Takeda, J.; Kishimoto, T.; Akira, s. J. Immunol.
1998, 16, 4652-4660; Teague, T. K.; Marrack, P.; Kappler, J. W.; Vella, A. T. J.
Immunol. 1997, 158, 5791-5796; Van Snick, J. Annu. Rev. Immunol. 1990, 8, 253-278;
Lotz, M. Vaughan, J. H.; Carson, D. A. Science 1988, 241, 1218-1221.
![Page 168: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/168.jpg)
167
41. Weissenbach, M.; Clahsen, T.; Weber, C.; Spitzer, D.; Wirth, D.; Vestweber, D.;
Heinrich, P. C.; Schaper, F. Eur. J. Immunol. 2004, 34, 2895-2906.
42. Delens, N.; Torreele, E.; Savelkool, H.; De Baetselier, P.; Bouwens, L. Int. J. Cancer
1994, 57, 696-700; Bacon, K.; Gearing, A.; Camp, R. Cytokine 1990, 2, 100-105.
43. Mitsuyama, K.; Sata, M.; Rose-John, S. Cytokine Growth Factor Rev. 2006, 17,
451-461; Van Kemseke, C.; Belaiche, J.; Louis, E. Int. J. Colorectal Dis. 2000, 15, 206-
210.
44. Uwasaki, A.; Medzhitov, R. Nat Immunol., 2004, 5, 987-995.
45. Pasare, C.; Medzhitov, R. Immunity, 2004, 21, 7333-741.
46. Takeda, K.; Kaisho, T.; Akira, S. Annu Rev Immunol. 2003, 21, 335-376.
47. Rakoff-Nahoum, S.; Paglino, J.; Eslami-Varzaneh, F.; Edberg, S.; Medzhitov, R.
Cell, 2004, 118, 229-241.
48. Ulevitch, R. J.; Tobias, P. S. Annu. Rev. Immunol. 1995, 12, 437-457; Yamamoto,
S.; Ishida, T.; Inoue, A.; Mikami, J.; Muraguchi, M.; Ohmoto, Y.; Kiwada, H. Int. J.
Pharm. 2002, 236, 125-133; Pasare, C.; Medzhitov, R. Immunity 2004, 21, 733-741;
Kubo, T.; Hatton, R. D.; Oliver, J.; Liu, X.; Elson, C. O.; Weaver, C. T. J. Immunol. 2004,
173, 7249-7258; Wang, M.; Tan, Z.; Thomas, E. K.; Liang, P. Genes Immun. 2004, 5,
363-370; Yang, L.; Mosmann, T. Eur. J. Immunol. 2004, 34, 1617-1626.
49. Lucas, A. H.; Apicella, M. A.; Taylor, C. E. Clin. Infect. Diseases, 2005, 41, 705-712.
50. Kowalczky, I. Acta. Chim. Slov. 2014, 61, 39-50.
51. Walsh, C. L.; Nguyen, J.; Szoka, F. C. Chem. Commun. 2012, 48, 5575-5577.
52. Shimizu, T.; Goda, T.; Minoura, T.; Takai, M.; Ishihara, K. Biomaterials 2010, 31,
3274-3280; Matsuno, R.; Takami, K.; Ishihara, K. Langmuir 2010, 26, 13028-13032; Xu,
![Page 169: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/169.jpg)
168
Y.; Takai, M.; Ishihara, K. Biomaterials 2009, 30, 4930-4938; Kyomoto, M.; Moro, T.;
Miyaji, F.; Hashimoto, M.; Kawaguchi, H.; Takatori, Y.; Nakamura, K.; Ishihara, K. J.
Biomed. Mater. Res. A 2009, 90A, 362-371.
53. Shan, B.; Yan, H.; Shen, J.; Lin, S. C. J. Appl. Polym. Sci. 2006, 101, 3697-3703;
Liu, P. S.; Chem, Q.; Liu, X.; Yuan, B.; Wu, S. S.; Shen, J.; Lin, S. C.
Biomacromolecules 2009, 10, 2809-2816.
54. Jiang, S. Y.; Cao, Z. Q. Adv. Mater. 2010, 22, 920-932; Zhang, Z.; Cheng, G.; Carr,
L. R.; Vaisocherova, H.; Chen, S. F.; Jiang, S. Y. Biomaterials 2008, 29, 4719-4725;
Zhang, Z.; Chen, S. F.; Jiang, S. Y. Biomacromolecules 2006, 7, 3311-3315; Cheng, G.;
Mi, L.; Cao, Z. Q.; Xu, H.; Yu, Q. M.; Carr, L.; Jiang, S. Y. Langmuir 2010, 26, 6883-
6886.
55. Huang, J.; Gu, S.; Zhang, R.; Xia, Z.; Xu, W. J. Therm. Anal. Calorim. 2013, 112,
1289-1295.
56. Hossain, N.; Ivanova, S.; Timen, A. S.; Bergare, J.; Mussie, T.; Bergstrom, L.
Bioorg. Med. Chem. Lett. 2013, 23, 4026-4030.
57. Wu, X.; Cui, L.; Lipinski, T.; Bundle, D. R. Angew. Chem. 2010, 16, 3476-3488.
58. Christina, A. E.; van den Bos, L. J.; Overkleeft, H. S.; van der Marel, G. A.; Codee,
J. D. C. J. Org. Chem. 2011, 76, 1692-1706.
59. van den Bos, L. J.; Boltje, T. J.; Provoost, T.; Mazurek, J.; Overkleeft, H. S.; van der
Marel, G. A. Tetrahedron Lett. 2007, 48, 2697-2700.
60. Pragani, R.; Seeberger, P. H. J. Am. Chem. Soc. 2010, 133, 102-107.
61. Ge, P.; Kirk, K. L. J. Org. Chem. 1996, 61, 8671-8673.
62. Ren, F.; Hogan, P.; Anderson, A. J.; Myers, A. G. Org. Lett. 2007, 9, 1923-1925.
![Page 170: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/170.jpg)
169
63. Kocienski, P.; Narquizian, R.; Raubo, P.; Smith, C.; Farrugia, L. J.; Muir, K.; Boyle,
F. T. J. Chem. Soc., Perkin Trans. 1 2000, 2357-2384.
64. Luche, J. L. J. Am. Chem. Soc. 1978, 100, 2226-2227.
65. Lemieux, R. U.; Ratcliffe, R. M. Can. J. Chem. 1979, 57, 1244-1251.
66. Gauffeny, F.; Marra, A.; Shun, L. K. S.Sinay, P.; Tabeur, C. Carbohydr. Res. 1991,
219, 237-240.
67. Pragani, R.; Stallforth, P.; Seeberger, P. H. Org. Lett. 2010, 12, 1624-1627.
68. Completo, G. C.; Lowary, T. L. J. Org. Chem. 2008, 73, 4513-4525.
69. Dhenin, S. G. Y.; Moreau, V.; Morel, N.; Nevers, N. C.; Volland, H.; Creminon, C.;
Djedaini-Pilard, F. Carbohydr. Res. 2008, 343, 2101-2110.
70. Mogemakr, M.; Elofsson, M.; Kihlberg, J. J. Org. Chem. 2003, 68, 7281-7288.
71. Ziegler, T. Tetrahedron Lett. 1994, 35, 6857-6860.
72. Fugedi, P.; Garegg, P. J. Carbohydr. Res. 1986, 149, C9-C12.
73. Pearlman, W. M. Tetrahedron Lett. 1967, 17, 1663-1664.
74. Tzianabos, A. O.; Finberg, R. W.; Wang, Y.; Chan, M.; Onderdonk, A. B.; Jennings,
H. J.; Kasper, D. L. J. Biol. Chem. 2000, 275, 6733-6740.
75. Tzianobus, A. O.; Onderdonk, A. O.; Zaleznik, D. F.; Smith, R. S.; Kasper, D. L.
Science 1993, 262, 416-419.
76. Balcerzak, A. K.; Ferreira, S. S.; Trant, J. F.; Ben, R. N. Bioorg. Med. Chem. Lett.
2012, 22, 1719-1721.
77. Zemplen, G.; Pacsu, E. Ber. Dtsch. Chem. Ges. 1929, 62, 1613-1614.
78. Crich, D.; Hutton, T. K.; Banerjee, A.; Jayalath, P.; Picione, J. Tetrahedron
Asymmetry 2005, 16, 105-119.
![Page 171: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/171.jpg)
170
79. Gomez, A. M.; Pedregosa, A.; Valverde, S.;Lopez, J. C. ARKIVOC 2011, 3, 33-41.
80. Frankowski, A.; Deredas, D.; Le Nouen, D.;Tschamber, T.; Streith, J. Hel. Chim.
Acta. 1995, 78, 1837-1842.
81. Reginato, G.; Ricci, A.; Roelens, S. Scapecchi, S. J. Org. Chem. 1990, 55, 5132-
5139.
82. Lu, W.; Navidpour, L.; Taylor, S. D. Carbohydr. Res. 2005, 340, 1213-1217.
83. Wessel, H-P; Iversen, T.; Bundle, D. R. J. Chem. Soc. Perkin Transaction I 1985,
2247-2250.
84. Ikemoto, N , Schreiberm S. L. J. Am. Chem. Soc. 1992, 114, 2524-2536; Hiruma,
K.; Kajimoto, T.; Weitz-Schmidt, G.; Oilmann, I.; Wong, C. –H. J. Am. Chem. Soc. 1996,
118, 9265-9270.
85. Wynne, G. M.; Storer, R. PCT Int. Appl. 2008, 82pp. CODEN:PIXXD2;
WO2008007153.
86. Ziegler, T.; Herold, G. Liebigs Ann. Chem. 1994, 859-866.
87. Horton, D. Org. Synth. 1973, 5, 1-3; Horton, D. Org. Synth. 1966, 46, 1-3.
88. Guilbert, B.; Davis, N. J.; Pearce, M.; Aplin, R. T.; Flitsch, S. L. Tetrahedron
Asymmetry 1994, 5, 2163-2178.
89. Krag, J.; Christiansen, M. S.; Petersen, J. G.; Jensen, H. H. Carbohydr. Res. 2010,
345, 872-879.
90. Grant, L.; Liu, Y.; Walsh, K. E.; Walter, D. S.; Galagher, T. Org. Lett. 2002, 4, 4623-
4625.
91. Deng, S.; Gangadharmath, U.; Chang, C-W. T. J. Org. Chem. 2006, 71, 5179-5185.
92. Bongat, A.F. G.; Demchenko, A. V. Carbohydr. Res. 2007, 342, 374-406.
![Page 172: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/172.jpg)
171
93. Ch, R.; Tyagi, M.; Patil, P. R.; Kartha, K. P. R. Tetrahedron Lett. 2001, 52, 5841-
5846.
94. Ellervik, U.; Magnusson, G. Carbohydr. Res. 1996, 280, 251-260.
95. Song, Z. L.; Wang, B. M.; Tu, Y. Q.; Fan, C. A.; Zhang, S. Y. Org. Lett. 2003, 5,
2319-2321.
96. Tanifum, C. T.; Chang, C-W. T. J. Org. Chem. 2009, 74, 634-644.
97. Cerny, M. Adv. Carbohydr. Chem. Biochem. 2003, 58, 121.
98. Ball, D. H.; Parish, F. W. Adv. Carbohydr. Chem. Biochem. 1969, 24, 139.
99. Williams, N. R. Adv. Carbohydr. Chem. Biochem. 1970, 25, 109.
100. Cerny, M.; Stanek, J. Jr. Adv. Carbohydr. Chem. Biochem. 1977, 34, 23.
101. Ferrier, R. J.; Middleton, S. Chem. Rev. 1993, 93, 2779.
102. Saito, H. K.; Takaya, J. K.; Nahakata, S. H.; Oshima, A. I. J. Org. Chem. 2001, 66,
6982-6987.
103. Rees, D. A. Adv. Carbohydr, Chem, Biochem. 1969, 24, 267-332.
104. Hrebabecky, H.; Dockal, J.; Holy, A. Collect. Czech. Chem. Commun. 1994, 59,
1408-1419.
105. Hanessian, S. Total Synthesis of Natural Products: The Chiron Approach.
Pergamon Press, New York, 1983; Inch, T. D. Tetrahedron 1984, 40, 3161; Fraser-
Reid, B.; Tsang, R. Strategies and Tactics in Organic Synthesis, Academic Press, New
York, 1989.
106. Saito, H. K.; Takaya, J. K.; Nahakata, S. H.; Oshima, A. I. J. Org. Chem. 2001, 66,
6982-6987.
107. Rees, D. A. Adv. Carbohydr. Chem. Biochem. 1969, 24, 267-332.
![Page 173: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/173.jpg)
172
108. Peat, S. Adv. Carbohydr. Chem. 1946, 2, 37-77.
109. Schuerch, C. Adv. Carbohydr. Chem. Biochem. 2003, 58, 121-198.
110. Chiappe, C.; Moro, G. L.; Munforte, P. Tetrahedron 1997, 53, 10471-10478.
111. Eby, R.; Srivastava, V. K. Carbohydr. Res. 1982, 102, 1-9.
112. Yang, G.; Knog, F.; Fraser, R. R. Carbohydr. Res. 1994, 258, 49-58.
113. Brigl, P. Hoppe-Seyler’s Z. Physiol. Chem. 1922, 122, 245-262.
114. Lemieux, R. U.; Howard, J. Methods Carbohydr. Chem. 1963, 2, 400-402.
115. Frenzel, H.; Nunh, P.; Wagner, G. Archiv. Pharm. 1969, 302, 62-72.
116. Lemieux, R. U.; Huber, G. J. Am. Chem. Soc. 1956, 78, 4117-4119.
117. Halcomb, R. L.; Danishefsky, S. J. J. Am. Chem. Soc. 1989, 111, 6661-6666.
118. Marzabadi, C. H.; Spilling, C. D.; Tyler, L. M. Tetrahedron 1994, 50, 6783-6796.
119. Goog, F.; Schuerch, C. Carbohydr. Res. 1984, 125, 165-171.
120. Ito, H.; Eby, R.; Kramer, S.; Schuerch, C. Carbohydr. Res. 1980, 86, 193-202.
121. Kong, F.; Schuerch, C. Carbohydr. Res. 1983, 112, 141-149.
122. Xiong, S. Q.; Kong, F. Z.; Yang, F. Youji Huaxue 1994, 14, 280-285.
123. Kong, F.; Lu, D.; Zhou, S. Carbohydr. Res. 1990, 198, 141-148.
124. Gan, Z.; Kong, F. Carbohydr. Lett. 1994, 1, 27-30.
125. Wu, X.; Kong, F.; Lu, D. P.; Zhang, P. Carbohydr. Res. 1992, 229, 75-87.
126. Yang, C.; Cao, L.; Kong, F. J. Carbohydr. Chem. 1992, 11, 379-395.
127. Wu, E.; Kong, F.; Su, B. Carbohydr. Res. 1987, 161, 235-246.
128. Sato, T.; Nakumura, H.; Ohno, Y.; Endo, T. Carbohydr. Res. 1990, 199, 31-35.
129. Kamitakahara, H.; Nakatsubo, F.; Murakami, K. Mokuzai Gakkaishi 1994, 40, 302-
307.
![Page 174: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/174.jpg)
173
130. Yoshida, T.; Hattori, K.; Choi, Y. S.; Arai, M.; Funaoka, H.; Uryu, T. J. Polym. Sci.
Part A Polym. Chem. 1998, 36, 841-850.
131. Koll, P. Chem. Ber. 1973, 106, 3559-3564.
132. Bullock, C.; Hough, L.; Richardson, A.C. Carbohydr. Res. 1990, 197, 131-138.
133. Brimacombe, J. S.; Minshall, J.; Tucker, L. C. N. J. Chem. Soc., Perkin Trans.
1973, 1, 2691-2694.
134. Koll, P.; Deyhim, S.; Heyns, K. Chem. Ber. 1973, 106, 3565-3570.
135. Koyama, Y.; Harima, K.; Matsuzaki, K.; Uryu, T. J. Polym. Sci., Part A Polym.
Chem. 1985, 23, 2989-2998.
136. Fleetwood, A.; Hughes, V. Carbohydr. Res. 1999, 317, 204-209.
137. Hori, M.; Nakatsubo, F. Carbohydr. Res. 1998, 309, 281-286.
138. Hagino, A.; Yoshida, S.; Shinpuku, T.; Matsuzaki, K.; Uryu, T. Macromolecules
1986, 19, 1-7.
139. Micheel, F.; Klemer, A. Adv. Carbohydr. Chem. 1961, 16, 85-103.
140. Barnett, J. E. G. Carbohydr. Res. 1969, 9, 21-31.
141. Yamamoto, K.; Haga, M.; Tejima, S. Chem. Pharm. Bull. 1975, 23, 233-236.
142. Wisniewski, A.; Madaj, J.; Skorupowa, E.; Sokolowski, J. J. Carbohydr. Chem.
1994, 13, 873-880.
143. Micheel, F.; Baum, G. Chem. Ber. 1955, 88, 2020-2025.
144. Gent, P. A.; Gigg, R.; Penglis, A. A. E. J. Chem. Soc., Perkin Trans. 1976, 1, 1395-
1404.
145. Coleman, G. H. Methods Carbohydr. Chem. 1963, 2, 397-399.
146. Hicks, D. R.; Fraser-Reid, B. Synthesis 1974, 203-207.
![Page 175: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/175.jpg)
174
147. Frahn, J. L. Aust. J. Chem. 1980, 33, 1021-1024.
148. Jary, J.; Raich, I. Carbohydr. Res. 1993, 242, 291-295.
149. Haworth, W. N.; Owen, L. N.; Smith, F. J. Chem. Soc. 1941, 88-102.
150. Valentin, F. Collect. Czech. Chem. Commun. 1934, 6, 354-370.
151. Cifonelli, M.; Cifonelli, J. A.; Montgomery, R.; Smith, F. J. Am. Chem. Soc. 1955,
77, 121-125.
152. Defaye, J. Bull. Soc. Chim. France 1964, 8, 2686-2689; Crotti, P.; Bussolo, V. Di.;
Favero, L.; Gozzi, C.; Pineschi, M. Tetrahedron: Asymmetry 1964, 8, 2686-2689.
153. Horton, D.; Philips, K. D. Carbohydr. Res. 1973, 30, 367-374.
154. Piper, I. M.; MacLean, D. B.; Kvarnstrom, I.; Szarek, W. A. Can. J. Chem. 1983,
61, 2721-2728.
155. Claustre, S.; Bringaud, F.; Azema, L.; Baron, R.; Perie, J.; Willson, M. Carbohydr.
Res. 1999, 315, 339-344.
156. Chang, C. -D.; Hullar, T. L. Carbohydr. Res. 1977, 54, 217-230.
157. Montgomery, J. A.; Hewson, K.; Laseter, A. G. Carbohydr. Res. 1973, 27, 303-308.
158. Ogawa, T.; Matsui, M.; Ohrui, H.; Kuzuhara, H.; Emoto, S. Agric. Biol. Chem.
(Japan) 1972, 36, 1449-1451.
159. Defaye, J.; Ratovelomanana, V. Carbohydr. Res. 1971, 17, 57-65.
160. Levene, P. A. J. Biol. Chem. 1919, 39, 69-76.
161. Elbert, T.; Cerny, M.; Defaye, J. Carbohydr. Res. 1979, 76, 109-119.
162. Ogawa, T.; Matsui, M.; Ohrui, H.; Kuzuhara, H.; Emoto, S. Agric. Biol. Chem.
(Japan) 1972, 36, 1655-1657.
163. Schafer, S. E.; Stevens, E. S.; Dowd, M. K. Carbohydr. Res. 1995, 270, 217-220.
![Page 176: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/176.jpg)
175
164. Koll, P.; Komander, H.; Meyer, B. Liebigs Ann. Chem. 1983, 1310-1331.
165. Campbell, J. W.; Harding, M. M. J. Chem. Soc., Perkin Trans. 2 1972, 1721-1723.
166. Randall, M. H.; Angyal, S. J. J. Chem. Soc., Perkin Trans. 1 1972, 346-351.
167. Koll, P.; Tayman, F. S. Chem. Ber. 1979, 112, 2296-2304; Rosenfeld, D. A.;
Richtmyer, N. K.; Hudson, C. S. J. Am. Chem. Soc. 1948, 70, 2201-2206.
168. Koll, P.; Tayman, F. S.; Heyns, K. Chem. Ber. 1979, 112, 2305-2313; Castellano,
E. E.; Oliveira, M. A.; Baptisella, L. H. B.; Marsaioli, A. J.; Castillo, S.; Lukacs, G. Acta
Crystallogr. Section C: Struct. Commin. 1986, 42, 758-760.
169. Koll, P.; Komander, H.; Kopf, J. Chem. Ber. 1980, 113, 3919-3926.
170. Hughes, N. A.; J. Chem. Soc. C 1969, 2263-2266.
171. Koll, P.; Fortsch, A.; Kopf, J. J. Carbohydr. Chem. 1983, 2, 189-200; Koll, P.;
Komander, H. Liebigs Ann. Chem. 1981, 1960-1966.
172. Rosenfeld, D. A.; Richtmyer, N. K.; Hudson, C. S. J. Am. Chem. Soc. 1948, 70,
2201-2206.
173. Andersen, S. M.; Lundt, I.; Marcussen, J.; Yu, S. Carbohydr. Res. 2002, 337, 837-
890; Lichtenthaler, F. W.; El Ashry, E. S. H.; Gockel, V. H. Tetrahedron Lett. 2002, 337,
873-890.
174. Yu, S. Life 2008, 60, 798-809.
175. Jarosz, S.; Zamojski, A.; Curr. Org. Chem. 2003, 7, 13-33.
176. Saito, H. K.; Takaya, J. K.; Nahakata, S. H.; Oshima, A. I.; J. Org. Chem. 2001, 66,
6982-6987.
177. Rees, D. A.; Adv. Carbohydr. Chem. Biochem. 1969, 24, 267-332.
![Page 177: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/177.jpg)
176
178. Hrebabecky, H.; Dockal, J.; Holy, A. Collect. Czech. Chem. Commun. 1994, 59,
1408-1419.
179. Taylor, E. W.; Van Roey, P.; Schinazi, R. F.; Chu, C. K. Antiviral Chem.
Chemother. 1990, 1, 163-173.
180. a) Ford Jr, H.; Dai, F.; Mu, L.; Siddiqui, M. A.; Nicklaus, M. C.; Anderson, L.;
Marquez, V. E.; Barchi Jr, J. J. Biochemistry 2000, 39, 2581-2592; b) Marquez, V. E.;
Choi, Y.; Comin, M. A.; Russ, P; George, C.; Huleihel, M.; Ben-Kasus, T.; Agbaria, R. J.
Am. Chem. Soc. 2005, 127, 15145-15150; c) Jacobson, K. A.; Gao, Z. G.; Tchilibon, S.;
Duong, S. T.; Jpshi, B. V.; Sonin, D.; Liang, B. T. J. Med. Chem. 2005, 48, 8103-8107;
d) Costanzi, S.; Joshi, B. V.; Maddileti, S.; Mamedova, L.; Gonzalez-Moa, M. J.;
Marquez, V. E.; Harden, T. K.; Jacobson, K. A. J. Med. Chem. 2005, 48, 8108-8111
181. Serrano, J. A.; Jiminez, M.; Roman, E. J. Carbohydr. Chem. 1997, 16, 1051-1059
182. Walker, E.; Roussel, P.; Jeanloz, R. W.; Reinhold, V. N. Carbohydr. Res. 1974, 35,
270-279.
183. Zu Reckendrof, W. M.; Schultz, N.; Kreimeier, R. Liebigs Ann. Chem. 1994, 337-
346.
184. Chapleur, Y.; Castro, B.; Gross, B. Synthesis 1983, 447-449.
185. Borbas, A.; Biro, A.; Liptak, A. ACH-Models Chem. 1994, 131, 455-465.
186. Tsuda, Y.; Shibayama, K. Chem. Pharm. Bull. 1996, 44, 1476-1479.
187. Molas, M. P.; Matheu, M. I.; Castillon, S.; Isac-Garcia, J.; Hernandez-Mateo, F.;
Calvo-Flores, F. G.; Santoyo-Gonzales, F. Tetrahedron 1996, 44, 1476-1479.
188. Koll, P.; Meyborg, H. Tetrahedron Lett. 1974, 4499-4500.
189. Araki, Y.; Arai, Y.; Endo, T.; Ishido, Y. Chem. Lett. 1989, 1-4.
![Page 178: Synthesis and Evaluation of Biological Activity of a ...](https://reader033.fdocuments.in/reader033/viewer/2022042216/6259b64ef5823a11b34179f7/html5/thumbnails/178.jpg)
177
190. Hama, Y.; Nahagawa, H.; Sumi, T.; Xia, X.; Yamaguchi, K. Carbohydr. Res. 1999,
318, 154-156.
191. Brimacombe, J. S.; Da’Aboul, I.; Tucker, L. C. N. Carbohydr. Res. 1971, 19, 276-
280.
192. Fraser-Reid, B.; Kelly, D. R.; Tulshian, D. B.; Ravi, P. S. J. Carbohydr. Chem.
1983, 2(2), 105-114.
193. Basava, V.; Gorun, S. M.; Marzabadi, C. H. Carbohydr. Res. 2014, 391, 106-111.
194. Zemplen, G.; Pacsu, E. Ber. Dtsch. Chem. Ges. 1929, 62, 1613-1614.
195. Fraser-Reid, B.; Kelly, D. R.; Tulshian, D. B.; Ravi, P. S. J. Carbohydr. Chem.
1983, 2(2), 105-114.
196. CCDC 988697 contains the supplementary crystallographic data for this paper.
These data can be obtained free of charge from The Cambridge Crystallographic Data
Centre via www.ccdc.cam.ac.uk/data_request/cif.
197. Wolff, R. R.; Basava, V.; Giuliano, R. M.; Boyko, W. J.; Schauble, J. H. Can. J.
Chem. 2006, 84 (4), 667-675.
198. Paul, S.; Jayaraman, N. Carbohydr. Res. 2004, 339, 2197-2204.
199. Roush, W. R.; Narayan, S.; Bennett, C. E.; Briner, K. Org. Lett. 1999, 1, 895-897.